5BARz International 10-K 15 Apr 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 20, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	5Barz International, Inc.
Entity Central Index Key	1454124
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$29,970,598
Entity Common Stock, Shares Outstanding		218,974,013
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
CURRENT ASSETS:
Cash	$25,103	$450,215
Inventories	165,091	161,900
Note receivable		65,000
Prepaid expenses and deposits	73,711	62,981
TOTAL CURRENT ASSETS	263,905	740,096
FIXED ASSETS:
Furniture and equipment, net	262,355	225,983
OTHER ASSETS:
Intangible assets, net	3,236,033	3,387,406
Goodwill	1,140,246	1,140,246
TOTAL OTHER ASSETS	4,376,279	4,527,652
TOTAL ASSETS	4,902,539	5,493,731
CURRENT LIABILITIES:
Accounts payable and accrued expenses	2,866,276	1,450,167
Due to escrow agent		52,321
Derivative liabilities	547,940	60,018
Capital lease obligation ( current portion )	70,000	60,000
Notes payable, net of debt discount	280,486	410,183
TOTAL CURRENT LIABILITIES	3,764,702	2,032,689
Related party loans
Capital lease obligation (non- current portion )	50,906	100,464
TOTAL LIABILITIES	3,815,608	2,133,153
STOCKHOLDERS' EQUITY
Common stock, $.001 par value, 400,000,000 shares authorized; 213,384,526 and 163,909,191 shares issued and outstanding as of December 31, 2014 and 2013, respectively	213,383	163,909
Capital in excess of par value	15,135,856	7,721,140
Accumulated deficit	-14,862,230	-5,173,598
Accumulated other comprehensive income	31,633	29,234
Non-controlling interest	568,289	619,893
TOTAL STOCKHOLDERS' EQUITY	1,086,931	3,360,578
TOTAL AND STOCKHOLDERS' EQUITY	$4,902,539	$5,493,731

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Common stock, par value	$0.00	$0.00
Common stock, authorized	400,000,000	250,000,000
Common stock, issued	213,384,526	163,909,191
Common stock,outstanding	213,384,526	163,909,191

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Sales
Cost of Sales
Gross profit
Operating expenses:
Amortization and depreciation	282,636	10,512
Bank charges and interest	74,473	59,056
Sales and marketing expenses	1,210,812	194,750
Research and development	4,123,841	806,047
General and administrative expenses	3,704,013	2,229,904
Total operating expenses	9,395,775	3,300,269
(Loss) from operations	-9,395,775	-3,300,269
Other income (expense):
Interest income	58
Change in fair value of derivative liability	-224,432	-60,018
Loss on conversion of debt		-17,500
Change in warrant liability		8,178
Interest expense - debt discount	-105,504
Liquidation expenses 5BARz AG	-14,583
Gain on debt settlements		1,073,009
Total other (expense) income	-344,461	1,003,669
Net (loss)	-9,740,236	-2,296,600
Net (loss) -non-controlling interest	-51,604	-94,101
Net (loss) - controlling interest	-9,688,632	-2,202,499
Basic loss per common share	($0.05)	($0.02)
Weighted average number of shares outstanding	179,383,808	126,639,034
Other comprehensive income
Foreign currency translation gain	2,399	24,962
Other comprehensive income	2,399	24,962
Comprehensive loss	($9,686,233)	($2,177,537)

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($9,740,236)	($2,296,600)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation	282,636	10,512
Stock based compensation	1,676,676	601,113
Change in fair value of derivative liability	224,432	60,018
Change in warrant liability		-8,178
Common shares issued for services	491,720	228,740
Gain on settlement of debts		-1,073,009
Interest expense- debt discount	105,504
Changes in operating assets and liabilities:
Change in inventory	-3,191	-161,900
Change in note receivable	65,000	-65,000
Change in accounts payable and accrued expenses	1,517,506	406,397
Change in prepaid expenses and deposits	-10,730	-40,825
Change in unpaid interest and penalties on notes payable	2,588	108,377
Change in due to escrow agent	-52,321
Net cash (used in) operating activities	-5,440,416	-2,230,355
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of intangible assets	-52,033
Purchase of furniture and equipment assets	-115,601	-62,293
Net cash used in investing activities	-167,634	-62,293
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes	400,000	35,000
Payments of amounts due to related party		-19,850
Proceeds used to settle notes payable	-53,997	-357,583
Proceeds from issuance of common stock	4,840,545	2,930,750
Proceeds from issuance of common stock by subsidiary - 5BARz AG	33,549	91,276
Principal payments of capital leases	-39,558	-10,000
Net cash provided by financing activities	5,180,539	2,669,593
Effect of foreign currency exchange	2,399	24,962
NET (DECREASE) INCREASE IN CASH	-425,112	401,907
CASH, BEGINNING OF YEAR	450,215	48,308
CASH, END OF YEAR	25,103	450,215
Supplementary disclosure of Cash Flow Information
Cash paid for interest	12,376	8,915
Cash paid for income taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES
Conversion of notes payable - CelLynx Group,Inc. & 5BARz	70,300	30,500
Replacement of common shares acquired with a convertible note		80,000
Issuance of convertible note in lieu of accounts payable		147,428
Shares issued to settle interest on notes payable		7,500
Settlement of accounts payable with common stock	105,000	1,270,193
Settlement of notes payable with common stock	66,700	514,398
Lease obligation	$120,906	$160,464

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders Equity (USD $)	Common Stock	Excess of Par Value	Accumulated Deficit	Other Comprehensive Income	Noncontrolling Interest	Total
Beginning Balance, Amount at Dec. 31, 2012	$117,418	$3,226,802	($2,971,099)	$4,272	$713,994	$1,091,387
Beginning Balance, Shares at Dec. 31, 2012	117,418,281
Issuance of Common Stock , shares	35,775,000
Issuance of Common Stock , amount	35,775	2,894,975				2,930,750
Shares issued for Services, shares	3,581,200
Shares issued for Services, amount	3,581	225,159				228,740
Conversion of convertible note, shares	25,000
Conversion of convertible note, amount	25	4,975				5,000
Shares issued for Debt, shares	8,689,710
Shares issued for Debt, amount	8,690	763,751				772,441
Shares sold by 5BARz AG		91,276				91,276
Stock option expense		592,622				592,622
Share price adjustment, shares	20,000
Share price adjustment, amount	20	-20				0
Net loss			-2,202,499		-94,101	-2,296,600
Foreign Currency Gain				24,962		24,962
Shares cancelled, Shares	-1,600,000
Shares cancelled, Amount	-1,600	-78,400				-80,000
Ending Balance, Amount at Dec. 31, 2013	163,909	7,721,140	-5,173,598	29,234	619,893	3,360,578
Ending Balance, Shares at Dec. 31, 2013	163,909,191
Issuance of Common Stock , shares	44,053,632
Issuance of Common Stock , amount	44,054	4,796,491				4,840,545
Shares issued for Services, shares	4,274,481
Shares issued for Services, amount	4,273	487,447				491,720
Conversion of convertible note, shares	447,222
Conversion of convertible note, amount	447	66,253				66,700
Shares issued for Debt, shares	700,000
Shares issued for Debt, amount	700	104,300				105,000
Shares sold by 5BARz AG		33,549				33,549
Stock option expense		1,478,733				1,478,733
Warrants issued for services		157,557				157,557
Warrants issued for debt agreement		132,688				132,688
Beneficial conversion feature		117,312				117,312
Stock paid compensation CelLynx		40,386				40,386
Net loss			-9,688,632		-51,604	-9,740,236
Foreign Currency Gain				2,399		2,399
Ending Balance, Amount at Dec. 31, 2014	$213,383	$15,135,856	($14,862,230)	$31,633	$568,289	$1,086,931
Ending Balance, Shares at Dec. 31, 2014	213,384,526

Organization_and_Going_Concern

Organization and Going Concern	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Going Concern	Note 1 – Organization and Going Concern
	The Company was incorporated under the laws of the State of Nevada on November 14, 2008. The Company was originally named “Bio-Stuff” and was a designated shell corporation from inception to the date of acquisition of the 5BARz assets.
	In 2010 the Company changed its name to 5BARz International, Inc. and the Company acquired a set of agreements for a 50% interest in certain intellectual property underlying the 5BARz™ products, and marketing rights. The 5BARz products are highly engineered wireless units referred to as “cellular network infrastructure devices”. The 5BARz™ device captures cell signal and provides a smart amplification and resend of that cell signal giving the user improved cellular reception in their home, office or while mobile. On March 29, 2012, 5BARz International, Inc. acquired a 60% controlling interest in CelLynx Group, Inc. ( the founder of the 5BARz technology) and a 60% interest in the intellectual property underlying the 5BARz™ products.
	On November 6, 2011, the Company incorporated a subsidiary Company in Zurich, Switzerland called 5BARz AG which is a 94.2% held subsidiary at December 31, 2014. This entity has been granted the license for the marketing and distribution rights for 5BARz™ products in Germany, Austria and Switzerland. .
	These financial statements reflect the financial position for the Company and its subsidiary companies 5BARz AG, CelLynx Group Inc. and its wholly owned subsidiary CelLynx Inc. as at December 31, 2014. Results of operations for subsidiary Companies are reflected only from the date of acquisition of that subsidiary for the period indicated in the respective statement.
	Going concern
	The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has made no revenue to date. The Company incurred losses of $9,740,236 and $2,296,600 during the year ended December 31, 2014 and 2013 respectively. Cash used in operating activities was $5,440,416 and $2,230,355 for the year ended December 31, 2014 and 2013 respectively. The Company is seeking additional sources of equity or debt financing, and there is no assurance these activities will be successful. These factors raise substantial doubt about the Company’s ability to continue as a going concern and the Company’s continued existence is dependent upon adequate additional financing being raised to develop its sales and marketing program for the sales of 5BARz product, to expand the Company’s product base and commence its planned operations.
	Management’s assessment of the significant mitigating factors include several quantitative and qualitative conditions which support the Company’s ability to continue as a going concern as follows;
		·	Continued ability to generate proceeds from private placements – since inception of the 5BARz business in 2008, the Company has financed operations through private placements and debt, with increased volumes in the recent year. The Company’s gross proceeds from private placements for the year ended December 31, 2014 was $4,840,545 compared to $2,930,750 in 2013. This represents an increase of 65% over the prior year.
		·	Delivery of Beta Products – In February 2014, the Company presented a commercial grade product in Barcelona during the Mobile World Congress. By August 2014 the Company delivered products for testing to a collaborative partner in Latin America, which is an international cellular network operator. In December 2014, that Company completed a further product for testing by a Tier 1, cellular network operator in India. The Company’s rate of development is accelerating.
	The accompanying consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

Summary_of_significant_account

Summary of significant accounting policies

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Summary of significant accounting policies

Note 2 - Summary of significant accounting policies

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles generally accepted in the United States of America

The accompanying consolidated financial statements include the accounts of 5BARz International Inc., and its 94.2% owned subsidiary, 5BARz AG, and it’s 60% owned subsidiary CelLynx Group, Inc. and that Company’s 100% owned subsidiary CelLynx, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

As the Company has not yet commenced any revenue-generating operations, does not have any cash flows from operations, and is dependent on debt and equity funding to finance its operations, the Company is considered an emerging growth company. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to commercialize the Company’s current technology before another company develops similar technology.

In June 2014, as discussed in Note, 2, the Financial Accounting Standards Board issued new guidance that removed all incremental financial reporting requirements from generally accepted accounting principles in the United States for development stage entities. The Company early adopted this new guidance effective June 30, 2014, as a result of which all inception-to-date financial information and disclosures have been removed from this report.

Cash

Cash and cash equivalents include cash in hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of one year or less.

Use of estimates

The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include impairment analysis for long lived assets, income taxes, litigation and valuation of derivative instruments. Actual results could differ from those estimates.

Concentration of credit risk

Cash includes deposits in accounts maintained at financial institutions.  Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash. The Company maintains balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits for the banks located in the United States. To date, the Company has not experienced any losses in such accounts.

Research and development costs

Research and development costs are charged to expense as incurred. The costs of materials and equipment that are required or constructed for research and development activities, and have alternative future uses (either in research and development, marketing or production), are classified as property and equipment and depreciated over their estimated useful lives.

Furniture and equipment

Furniture & equipment is recorded at historical cost and is depreciated using the straight-line method over their estimated useful lives. Leasehold improvements are being amortized over the shorter of the useful life or the remaining lease term.  The useful life and depreciation method are reviewed periodically to ensure that the depreciation method and period are consistent with the anticipated pattern of future economic benefits. Expenditures for maintenance and repairs are charged to operations as incurred while renewals and betterments are capitalized. Gains and losses on disposals are included in the results of operations. The useful life of the equipment is being depreciated over three to seven years.

Inventory

Inventories are carried at the lower of cost and net realizable value. Cost is determined using the weighted-average method.   As of December 31, 2014 the Company’s inventory included 988 units of Road Warrior cellular networks extenders.

Goodwill and other intangible assets

The Company accounts for goodwill and intangible assets in accordance with the accounting guidance which requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. The Accounting Standards Codification (“Codification”) requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment). Application of the goodwill impairment test requires judgment, including the identification of reporting units, assigning assets and liabilities to reporting units, assigning goodwill to reporting units, and determining the fair value. Significant judgment is required to estimate the fair value of reporting units which includes estimating future cash flows, determining appropriate discount rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value and/or goodwill impairment.

When testing goodwill for impairment, the Company may assess qualitative factors for some or all of its reporting units to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment for some or all of our reporting units and perform a detailed quantitative test of impairment (step 1). If the Company performs the detailed quantitative impairment test and the carrying amount of the reporting unit exceeds its fair value, the Company would perform an analysis (step 2) to measure such impairment. In 2013, the Company first performed a qualitative assessment to identify and evaluate events and circumstances to conclude whether it is more likely than not that the fair value of the Company’s reporting unit is less than its carrying amount. Based on the Company’s qualitative assessments, the Company concluded that a positive assertion can be made from the qualitative assessment that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount. In accordance with the Codification, the Company reviews the carrying value of its intangibles and other long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group, if any, exceeds its fair market value. No impairment was deemed to exist as of December 31, 2014 and 2013.

Long-Lived Assets Subject to Amortization

The Company amortizes intangible assets with finite lives over their estimated useful lives and reviews them for impairment annually or whenever an impairment exists. The Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. There were no long-lived assets impairment charges recorded during the years ended December 31, 2014 and 2013.

Revenue recognition

The Company's revenue recognition policies are in compliance with ASC Topic 605, “Revenue Recognition.”  Revenue is recognized at the date of shipment to customers, and when the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured.

Foreign currency translation

Transactions in foreign currencies have been translated into US dollars using the temporal method. The functional currency of the Company’s subsidiary 5BARz AG, is its local currency (Swiss Franc – CHF). Under this method, monetary assets and liabilities are translated at the year-end exchange rate. Non-monetary assets have been translated at the historical rate of exchange prevailing at the date of the transaction. Expenses have been translated at the exchange rate at the time of the transaction. Realized and unrealized foreign exchange gains and losses are included in operations.

Fair value of financial instruments

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities, approximate fair value due to the short-term nature of these instruments.

Fair value is defined as an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:

•

Level 1. Quoted prices in active markets for identical assets or liabilities.

•

Level 2. Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.

•

Level 3. Significant unobservable inputs that cannot be corroborated by market data.

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the assets that are measured at fair value on a recurring basis.

Consolidated

Quoted Prices in Active Markets for Identical Assets or Liabilities

Quoted Prices for Similar Assets or Liabilities in Active Markets

Significant

Balance Sheet

(Level 1)

(Level 2)

Unobservable

Inputs

(Level 3)

Derivative Liabilities:

31-Dec-14

$

547,940

$

—

$

—

$

547,940

31-Dec-13

$

60,018

$

—

$

—

$

60,018

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:

31-Dec-14

31-Dec-13

Beginning balance

$

60,018

$

—

Aggregate fair value of conversion feature upon issuance

263,490

57,995

Change in fair value of derivative liabilities

224,432

2,023

Ending balance

$

547,940

$

60,018

The derivative conversion feature liabilities are measured at fair value using the Black-Scholes pricing model and are classified within Level 3 of the valuation hierarchy. The significant assumptions and valuation methods that the Company used to determine fair value and the change in fair value of the Company’s derivative financial instruments are provided below:

31-Dec-14

31-Dec-13

Stock price

$

0.11

$

0.25

Volatility

83

%

211

%

Risk-free interest rate

0.46

%

0.04

%

Dividend yield

0

%

0

%

Expected life

1.63 years

0.002 years

Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivate liabilities. For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, which reports to the Chief Financial Officer, determines its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department with support from the Company’s consultants and which are approved by the Chief Financial Officer.

Level 3 financial liabilities consist of the derivative liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.

The Company uses the Black-Scholes option valuation model to value Level 3 financial liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as, volatility.

As of December 31, 2014 there were no transfers in or out of Level 3 from other levels in the fair value hierarchy.

Derivative Instruments

The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging”. The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liability at the fair value of the instrument on the reclassification date.

Stock-Based Compensation

The Company records stock-based compensation in accordance with ASC Topic 718, “Compensation – Stock Compensation.” ASC 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the employee’s requisite service period. Under ASC 718, the Company’s volatility is based on the historical volatility of the Company’s stock or the expected volatility of similar companies. The expected life assumption is primarily based on historical exercise patterns and employee post-vesting termination behavior. The risk-free interest rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant.

The Company uses the Black-Scholes option-pricing model which was developed for use in estimating the fair value of options. Option-pricing models require the input of highly complex and subjective variables including the expected life of options granted and the Company’s expected stock price volatility over a period equal to or greater than the expected life of the options. Because changes in the subjective assumptions can materially affect the estimated value of the Company’s employee stock options, it is management’s opinion that the Black-Scholes option-pricing model may not provide an accurate measure of the fair value of the Company’s employee stock options. Although the fair value of employee stock options is determined in accordance with ASC 718 using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/seller market transaction.

The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

The Company incurred stock based compensation charges during the year ended December 31, 2014 and 2013 as follows;

Year ended

31-Dec

2014

2013

General and administrative

$

798,885

$

436,958

Research and development

452,427

164,155

Sales and marketing

425,364

—

Total

$

1,676,676

$

601,113

Income taxes

The Company accounts for income taxes in accordance with ASC Topic 740, “Income Taxes.” ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized.  Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Net loss per share

The Company reports loss per share in accordance with the ASC Topic 260, “Earnings Per Share.”, which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation.  In the accompanying financial statements, basic earnings per share of common stock is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants. These potentially dilutive securities of 102,517,763 and 49,855,171, respectively were not included in the calculation of loss per common share for the years ended December 31, 2014 or 2013 because their effect would be anti-dilutive. The weighted average number of shares outstanding does not include reciprocal shareholdings, held by the Company’s subsidiary, CelLynx Group, Inc. which is reflected as a reduction in capital in excess of par value on the Company’s balance sheet.

Recent Accounting Pronouncements

In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation." This ASU removes the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the ASU eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. This ASU is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company has elected to adopt this ASU effective with the June 30, 2014 Quarterly Report on Form 10-Q and its adoption resulted in the removal of previously required development stage disclosures.

In August 2014, the FASB issued ASU 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this ASU provide that guidance. In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for public and nonpublic entities for annual periods ending after December 15, 2016. Early adoption is permitted. The Company has elected to adopt this ASU effective with this Quarterly Report on Form 10-Q and its adoption resulted in the additional disclosures in note 1, reflecting management’s assessment of the mitigating effect of management’s plans on the Company’s ability to continue as a going concern.

FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2014 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2014 or 2013, and it does not believe that any of those pronouncements will have a significant impact on our consolidated financial statements at the time they become effective.

Furniture_and_equipment

Furniture and equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Furniture and equipment	Note 3 – Furniture and equipment
	Furniture and equipment consisted of the following at December 31, 2014 and December 31, 2013:
			31-Dec-14			31-Dec-13
	Office furniture and equipment		$	137,148		$	70,804
	Research and development equipment (i)			169,350			169,350
	Leasehold improvements			46,318			6,940
				352,816			247,094
	Accumulated amortization and depreciation			(90,461	)		(21,111	)
	Furniture and equipment, net		$	262,355		$	225,983
		(i)	The research and development equipment was subject to the terms of a capital lease agreement. (See Note 9)
	During the year ended December 31, 2014 the Company incurred amortization and depreciation expense of $79,230, (2013 - $10,985).

Long_lived_assets_subject_to_a

Long lived assets subject to amortization	12 Months Ended
	Dec. 31, 2014
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Long lived assets subject to amortization	Note 4 – Long lived assets subject to amortization
	Intangible assets are comprised of technology, trademarks and license rights which are recorded at cost.
			31-Dec-14				31-Dec-13
	Technology		$	3,067,827			$	3,015,794
	Marketing and distribution agreement			370,000				370,000
	Trademarks			264				264
	License rights			1,348				1,348
				3,439,439				3,387,406
	Accumulated amortization			(203,406	)			—
	Technology and other intangibles, net		$	3,236,033			$	3,387,406
	On August 2, 2014, the company commenced amortization of technology and other intangibles upon delivery of commercial beta devices for testing to a collaboration partner. During the year ended December 31, 2014, $203,406 was recorded as amortization on technology and other intangibles and nil during year ended December 31, 2013. The Company’s estimated technology amortization over the next five years is expected to be $2,191,306.
	The estimated amortization of intangible assets for the five years ended December 31, 2019 and thereafter is as follows:
	For the years ended				Total				Technology		Marketing and
	December 31,										distribution agreement		Trademark & license
													agreements
		2015			$	491,441			$	438,261	$	52,857	$	323
		2016				491,440				438,261		52,857		322
		2017				491,440				438,261		52,857		322
		2018				491,440				438,261		52,857		322
		2019				491,119				438,262		52,857		0
		Future years				779,153				695,462		83,691		0
					$	3,236,033			$	2,886,768	$	347,976	$	1,289

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Note 5 - Goodwill
	The changes in the carrying amount of goodwill for the years ended December 31, 2014 and December 31, 2013 is as follows:
		31-Dec-14		31-Dec-13
	Goodwill – beginning of year	$	1,140,246	$	1,140,246
	Goodwill – end of year	$	1,140,246	$	1,140,246

Income_taxes

Income taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income taxes	Note 6 - Income taxes:
	The domestic and foreign components of income (loss) before income taxes from continuing operations are as follows:
		31-Dec-14			31-Dec-13
	Domestic	$	(9,622,324	)	$	(2,251,545	)
	Foreign		(117,912	)		(45,055	)
	Loss from continuing operations before provision for income taxes	$	(9,740,236	)	$	(2,296,600	)
	The income tax provision (benefit) consists of the following:
		31-Dec-14			31-Dec-13
	Foreign
	Current	$	0		$	0
	Deferred		(25,941	)		(9,912	)
	U.S. federal
	Current		0			0
	Deferred		(2,897,734	)		(604,970	)
	State & local
	Current		0			0
	Deferred		(30,938	)		(214,066	)
	Total		(2,954,613	)		(828,948	)
	Change in valuation allowance		2,954,613			828,948
	Income tax provision (benefit)	$	0		$	0
	The provision (benefit) for income taxes using the statutory federal tax rate as compared to the Company’s effective tax rate is summarized as follows:
		31-Dec-14			31-Dec-13
	U.S. federal statutory income tax rate (benefit)		(34.0	%)		(34.0	%)
	State income taxes		(0.4	%)		(5.8	%)
	Stock based compensation		0	%		10.4	%
	Other permanent differences		4.1	%		1.5	%
	Change in valuation allowance		30.3	%		27.9	%
	Effective rate		0	%		0	%
	The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following:
		31-Dec-14			31-Dec-13
	Deferred tax assets
	Net operating loss carryovers	$	4,466,003		$	2,077,660
	R&D credit		321,482			66,017
	Accrued compensation		37,796			202,375
	Stock-based compensation		358,762			2,833
	Derivative liability		76,739			0
	Total deferred tax assets		5,260,782			2,348,886
	Valuation allowance		(5,117,872	)		(2,163,259	)
	Deferred tax asset, net of valuation allowance		142,910			185,626
	Deferred tax liabilities
	Fixed asset depreciation		(11,347	)		(14,024	)
	Intangible asset amortization		(54,824	)		(171,602	)
	Convertible debt		(76,739	)		0
	Total deferred tax liabilities		(142,910	)		(185,626	)
	Net deferred tax asset (liability)	$	0		$	0
	The Company is in the process of filing it’s federal and state tax returns for the years ended December 31, 2014 through 2011. The NOL’s for these years will not be available to reduce future taxable income, if any, until the returns are filed.
	As of December 31, 2014 and 2013, the Company had approximately $12,757,884 and $5,398,527 of U.S. federal and state net operating loss carryovers (“NOL’s”), respectively, to offset future taxable income. The U.S. federal and state net operating loss carryovers begin expiring in 2025. In accordance with section 382 of the Internal Revenue Code, deductibility of the Company’s U.S. net operating loss carryovers may be subject to an annual limitation in the event of a change of control. Management has performed a preliminary evaluation as to whether a change in control has taken place, and has concluded that there was a change of control with respect to the NOL’s of CelLynx Group, Inc. when the Company acquired its 60% ownership interest in March 2012.
	Therefore, the NOL’s of CelLynx Group Inc. will be subject to an annual limitation of approximately $8,700 as determined under the regulations. Due to the annual limitation, management has determined that $8,600,000 of the NOL’s of CelLynx Group, Inc. will expire unused and has reduced the related deferred tax asset accordingly.
	As of December 31, 2014 and 2013, the Company had Swiss Net operating loss carryovers of $372,780 and $254,868, respectively. The Swiss Net operating loss carryovers begin expiring in 2019.
	In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, Management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance for all periods. For the years ended December 31, 2014 and 2013, the change in the valuation allowance was $2,954,613 and $828,948, respectively.
	The Company evaluated the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as "unrecognized benefits." A liability is recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise's potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740.
	Interest costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as "Interest expense, net" in the statements of operation. Penalties would be recognized as a component of "General and administrative expenses."
	No interest or penalties were recorded during the year ended December 31, 2014 and December 31, 2013. As of December 31, 2014 and December 31, 2013 no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year.
	Foreign earnings are considered to be indefinitely reinvested; accordingly, no provision for U.S. federal and state income taxes has been provided thereon. Upon repatriation of earnings, in the form of dividends or otherwise, the Company would be subject to both U.S. income taxes (subject to an adjustment for foreign tax credits). Determination of the amount of unrecognized deferred U.S. income tax liability is not practicable.

Sales_of_Stock

Sales of Stock	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Common Stock	Note 7 - Sales of common stock
	During the years ended December 31, 2014 and 2013, the Company has issued shares of common stock as follows:
	On January 25, 2013 the Company issued 100,000 shares and warrants in settlement of accounts payable for services rendered in the amount of $5,000.
	On February 12, 2013 the Company issued 125,000 shares of common stock at a price of $0.06 per share as partial settlement of $7,500 due under a note payable.
	On February 15, 2013 the Company issued 1,440,000 shares of common stock at a price of $0.05 per share, for services with a total value of $72,000.
	On February 26, 2013 the Company issued 250,000 shares of common stock at a price of $0.04 per share, in settlement of accounts payable with a total value of $10,000.
	On February 26, 2013 the Company issued 91,780 shares of common stock at a price of $0.05 per share, in settlement of accounts payable with a total value of $4,589.
	On March 1, 2013 the Company issued 175,000 shares of common stock at a price of $0.05 per share, for services with a total value of $8,750.
	On March 1, 2013 the Company issued 600,000 shares of common stock at a price of $0.05 per share, for aggregate proceeds of $30,000.
	On March 17, 2013 the Company issued 513,827 shares of common stock at a price of $0.05 per share, in settlement of accounts payable with a total value of $25,691.
	On March 31, 2013 the Company issued 100,000 shares of common stock at a price of $0.05 per share, in settlement of accounts payable with a total value of $5,000.
	During the period from January 4, 2013 to June 21, 2013 the Company issued 11,735,000 units at a price of $0.05 per unit for aggregate proceeds of $586,750. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.20 per share acquired, with a two year warrant term.
	On April 1, 2013 the Company issued 425,000 shares and warrants, with a two year term and $0.20 exercise price, in settlement of accounts payable with a total value of $21,250.
	On April 10, 2013 the Company issued 600,000 shares of common stock at a price of $0.05 per share, for aggregate proceeds of $30,000.
	On May 15, 2013 the Company issued 200,000 shares of common stock at a price of $0.05 per share for services with a total value of $10,000.
	On May 23, 2013 the Company issued 200,000 shares and warrants, with a two year term and $0.20 exercise price, in settlement of accounts payable with a total value of $10,000.
	On May 28, 2013 the Company issued 100,000 shares of common stock at a price of $0.05 per share, for debt with a total value of $5,000.
	On July 1, 2013 the Company issued 331,200 shares and warrants, with a two year term and $0.20 exercise price, for services with a total value of $66,240.
	During the period July 25, 2013 to March 6, 2014 the Company issued 29,215,000 units at a price of $0.10 per unit for aggregate proceeds of $2,921,500. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.30 per share acquired, with a two year term on the attached warrant.
	During the period from September 5, 2013 to November 18, 2013 the Company issued 6,044,108 units at a price of $0.10 per unit in order to settle debts, with a total value of $604,411. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.30 per share acquired, with a two year term on the attached warrant.
	On November 15, 2013 the Company issued 25,000 shares as partial conversion of a note payable at a price of $0.20 per share for a total debt reduction of $5,000.
	On January 15, 2014 the Company issued 100,000 shares at a price of $0.167 per share for the settlement of notes payable with a total value of $16,700.
	During the period January 31, 2014 to March 5, 2014 the Company issued 6,550,000 units at a price of $0.10 per unit for aggregate proceeds of $655,000. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.30 per share acquired, with a two year term on the attached warrant.
	On February 10, 2014 the Company issued 405,581 shares at a price of $0.2465 per share for services with a total fair value of $100,000.
	On February 10, 2014 the Company issued 1,250,000 shares at a price of $0.23 per share for services with a total fair value of $287,500.
	During the period March 6, 2014 to November 14, 2014 the Company issued 23,103,632 units at a price of $0.15 per unit for aggregate proceeds of $3,465,545. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.30 per share acquired, with a two year term on the attached warrant.
	During the period April 28, 2014 to September 15, 2014 the Company issued 325,000 units at a price of $0.15 per unit for services with a total value of $48,750. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.30 per share acquired, with a two year term on the attached warrant.
	On May 1, 2014 the Company issued 2,000,000 shares for services valued at $160,000.
	On May 29, 2014 the Company issued 347,222 shares at a price of $0.144 per share for the settlement of notes payable with a total value of $50,000.
	During the period June 1, 2014 to September 30, 2014 the Company issued 200,000 shares at a price of $0.20 and $0.21 per share for services with a total fair value of $40,250.
	On July 8, 2014 the Company entered into a settlement for debt agreement with the Chairman of the Board, in the amount of $105,000. Pursuant to the terms of the agreement the Company issued 700,000 units at a price of $0.15 per unit. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.20 per share acquired, with a two year term on the attached warrant.
	On July 16, 2014 the Company issued 11,400 shares at a price of $0.05 per share for services with a total fair value of $570.
	On August 14, 2014 the Company issued 32,500 shares at a price of $0.22 per share for services with a total fair value of $7,150.
	On October 1, 2014 the Company issued 25,000 shares at a price of $0.17 per share for services with a total fair value of $4,250.
	On November 1, 2014 the Company issued 25,000 shares at a price of $0.14 per share for services with a total fair value of $3,500.
	During the period November 21, 2014 to December 31, 2014 the Company issued 14,400,000 units at a price of $0.05 per unit for aggregate proceeds of $720,000. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.30 per share acquired, with a two year term on the attached warrant.

Notes_payable

Notes payable	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Notes payable	Note 9 – Notes payable
	Promissory Notes
	5BARz International, Inc.		Unpaid		Note	Unpaid		Balance			Balance
			Note Principal		Terms	Interest		31-Dec-14			31-Dec-13
	Issue Date
	3-Feb-12			—	(a)		—		—			103,997
	17-Dec-12			80,000	(b)		13,045		93,045			86,645
	8-Jan-13			96,313	(c)				96,313			154,017
	21-Aug-14			150,000	(d)		34,667		184,667			—
	6-Oct-14			250,000	(e)		623		250,623
	Notes payable – 5BARz International Inc.		$	576,313		$	48,335	$	624,648		$	344,659
	CelLynx Group Inc.
	24-May-12			15,900	(f)		21,248		37,148			37,822
	12-Sep-12			12,500	(g)		14,176		26,676			27,702
	Notes payable CelLynx Group, Inc.		$	28,400		$	35,424	$	63,824		$	65,524
	Sub-Total		$	604,713		$	83,759	$	688,472		$	410,183
	Debt Discount			—			—		(407,986	)		—
	Total, net of debt discount		$	604,713		$	83,760	$	280,486		$	410,183
	a)	In January 2012, the Company negotiated potential agreements for a convertible debenture and an equity investment agreement with a private investment firm (La Jolla). On February 3, 2012 the investment firm advanced $100,000, and on June 8, 2013 they advanced $50,000 to the Company. As contemplated, the convertible debenture agreement provided that the investor could invest up to $500,000 and convert the principal and unpaid interest into a certain number of shares, 180 days from the date of the agreement. On August 2, 2012 and August 13, 2012, the Company received conversion notices that materially conflict with the parties’ negotiations and the terms of the agreement. The Company offered to repay the amounts invested along with accrued interest and additional share compensation, but arrived at no settlement.
		On October 16, 2012, the investment firm filed a complaint in the federal court for the Northern District of California claiming breach of contract and seeking compensatory damages. On January 3, 2013, the Company entered into a settlement agreement requiring payments in the aggregate amount of $300,000 yielding interest at 9%, and the issuance of 125,000 shares of the common stock of the Company. The Company issued the 125,000 shares on February 12, 2013. During the period from May 22, 2013 to March 31, 2014 the Company made a series of payments aggregating $325,939 representing principal and interest required, which is paid in full as of December 31, 2014.
	b)	In December 2012, a shareholder purchased 1,600,000 common shares for $80,000. On January 17, 2013, the security was amended to a convertible debenture with an 8% per annum yield and may be converted into common stock, at the option of the holder, 90 days after the inception of the agreement, at a price which is a 20% discount to market, but not less than $0.05 per share.  During the period from issuance of the convertible debenture to December 31, 2014, interest of $13,045 was accrued on the convertible debenture, resulting in a total principal and interest due at December 31, 2014 of $93,045. In connection with the convertible debt, the Company recorded $23,262 of derivative liability as of December 31, 2014.
	c)      On January 8, 2013 the Company entered into a convertible debenture agreement with a consultant in settlement of $147,428 payable to that consultant for services rendered. The convertible debenture yields interest at 8% per annum and may be converted into common stock, at the option of the holder, 90 days after the inception of the agreement, at a price which is a 20% discount to market, but not less than $0.05 per share.  During period from January 8, 2013 to December 31, 2014, interest of $20,584 was accrued on the convertible debenture.  On November 15, 2013, $5,000 was paid on the note by way of conversion to common stock and during the year ended December 31, 2014 a further $66,700 was paid on the note by way of conversion to common stock. At December 31, 2014 principal due on the note was $96,313. In connection with the convertible debt, the Company recorded $24,079 of derivative liability as of December 31, 2014.
	d)      On August 21, 2014 the Company entered into a convertible note arrangement with an investment company, in the principal amount of $500,000 of which $150,000 was advanced to the Company at the inception of the note. The Company agreed to pay an “original issue discount” in an amount up to 10% of the loan amount, or $16,667. The loan could have been repaid at any time during the first three months of the note term. Thereafter, if the note is not repaid, a onetime interest charge of 12% will be assessed. As of December 31, 2014 the note has not been repaid. On November 19, 2014, $18,000 in interest was accrued resulting in a total principal and interest due at December 31, 2014 of $186,667. The note is convertible into common stock of the issuer at a discount to market of 40%, with the market defined as the lowest trade price for a period of 25 days prior to the conversion, with a conversion floor price at no lower than $0.00005. The ceiling price on the conversion is set at $0.22 per share. In connection with the convertible debt, the Company recorded $500,599 of derivative liability as of December 31, 2014.
	e)      On October 6, 2014 the Company entered into a Note and Warrant purchase agreement with three parties who have agreed to provide to the Company additional resources to run operations. The parties have agreed to loan up to $1,500,000 pursuant to the terms of a convertible promissory note and warrant agreement. On the closing date, October 6, 2014 the Company received $250,000 cash. The purchasers have agreed that at any time on or before the earlier of (i) the Purchasers’ election, or (ii) the execution of an engagement letter by and between the Company and an Investment Banking Firm acceptable to the purchaser relating to the provision of financial advisory services by the Investment Banking Firm to the Company, that the Company will sell Notes representing the balance of the authorized principal amount not sold at the Closing to the Purchasers. The convertible note accrues interest at a rate of 1% per annum and provides for the conversion of the principal and accrued interest on the note into common stock at any time, at the election of the holder at a price of $0.15 per share. Further, the number of warrants to be issued will be equal to the proceeds loaned pursuant to the note and warrant purchase agreement divided by $0.15. The warrant has a term of five (5) years and provides a strike price of $0.20 per share. The fair value of warrants at the date of issue was $282,767 using the Black Scholes pricing model. The convertible promissory note and accrued interest is calculated to be $250,623 at December 31, 2014, net of an unamortized debt discount of $223,319, resulting in a carrying value of $27,304. The unamortized debt discount of $223,319 will be charged to interest expense over the remaining term of the Note which matures December 31, 2016.
	f)      On May 24, 2012, CelLynx Group, Inc., completed a transaction pursuant to a Promissory Note agreement, through which the Company borrowed $37,500. The Note bears interest at a rate of 8%, and was due on November 24, 2012, (the “Due Date”).  The Company could settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principal amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principal amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note and accrued interest are convertible into common stock at a variable conversion price equal to 51% of the average of the three lowest closing bid prices for CelLynx Group, Inc’s common stock for a period of 10 days prior to the date of notice of conversion. The Company redeemed $21,600 payable on that note, by the issuance of CelLynx Group, Inc. common shares. As of December 31, 2014 the note is past due.  The value of the derivative liability associated with this note at December 31, 2014 and 2013 was immaterial. The note principal and accrued interest outstanding at December 31, 2014 was $37,148.
	(g)	On September 12, 2012, CelLynx Group, Inc. completed a transaction pursuant to a Promissory Note agreement, through which the Company borrowed $12,500. The Note bears interest at a rate of 8%, and is due on March 12, 2013, (the “Due Date”).  The Company may settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principal amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principal amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note and accrued interest are convertible into common stock at a variable conversion price equal to 51% of the average of the three lowest closing bid prices for CelLynx Group, Inc’s common stock for a period of 10 days prior to the date of notice of conversion. As of December 31, 2014 the note is past due.  The value of the derivative liability associated with this note at December 31, 2014 and 2013 was immaterial. The note was carried at $26,676 comprised of principal and interest due at December 31, 2014.

Capital_Lease_Obligation

Capital Lease Obligation	12 Months Ended
	Dec. 31, 2014
Capital Lease Obligations [Abstract]
Capital Lease Obligation	Note 10 – Capital Lease Obligation
	On November 1, 2013 the Company entered into a capital lease obligation for the acquisition of research and development equipment in San Diego, California. The lease requires a payment of $5,000 per month for thirty-six (36) months, representing minimum lease payments as follows;
		2015	$	75,000
		2016	$	50,000
		Total	$	125,000
		Interest (12%)	$	(4,094	)
		Capitalized valuation of equipment	$	120,906
	During the year ended December 31, 2014 and 2013 amortization expense of $58,802 and $7,056 was recorded on the R&D equipment respectively (see Note 3).
	Operating Lease Obligation
	On August 22, 2014 (the commencement date) the Company amended the terms of it’s leased facilities in San Diego, California. Pursuant to the terms of that amending agreement the Company extended the terms of its base lease for a further 66 months and in addition leased an expansion premises at the same location, also for 66 months. This lease, as amended represents aggregate minimum lease payments over the next five years and in aggregate as follows;
		2015	$	219,772
		2016	$	264,314
		2017	$	290,788
		2018	$	300,966
		2019	$	311,499
		Aggregate over 5 years	$	53,380
		Total	$	1,440,719

Options_and_Warrants

Options and Warrants	12 Months Ended
	Dec. 31, 2014
Options And Warrants
Options and Warrants	Note 11 – Options and Warrants
	Warrants – 5BARz International Inc.
	The following table summarizes the warrant activity to December 31, 2014:
		Number of			Weighted Average			Average Remaining
		Warrants			Exercise Price			Contractual Life
	Outstanding at December 31, 2013		47,580,103		$	0.26			1.64
	Granted*		34,920,294		$	0.28
	Exercised		—			—
	Cancelled		(540,000	)	$	0.2
	Outstanding at December 31, 2014		81,960,397		$	0.28			0.98
	Exercisable at December 31, 2014		81,960,397		$	0.28			0.98
	*During the year ended December 31, 2014, the Company granted 30,728,629 warrants as part of a unit in connection with various equity raises, 2,525,000 warrants were issued for services and 1,666,667 in connection with convertible notes issuances.
	Options – 5BARz International Inc.
	At December 31, 2014, 5BARz International, Inc. has the following Options outstanding;
		Number of Options			Weighted Average Exercise Price			Weighted Average
								Remaining Contractual
								Life (years)
	Outstanding – December 31, 2013		4,000,000			0.1			8.38
	Granted		8,250,000			0.17			5.37
	Outstanding – December 31, 2014		12,250,000			0.15			6.42
	Exercisable- December 31, 2014		12,250,000			0.15			6.42
	On May 17, 2013 the Company established the 2013 stock incentive plan for the Company. On that date 4,000,000 stock options were issued to officers of the Company to acquire common stock at a price of $0.10 per share. On January 13, 2014 the Company issued 4,150,000 options at a strike price of $0.17 per share, on May 14, 2014 the Company issued 2,000,000 options at a strike price of $0.17 per share, on July 14, 2014, the Company issued 100,000 options at a strike price of $0.17 per share, in addition on August 1, 2014, the Company issued 2,000,000 options at a strike price of $0.17 per share. The Company reports stock-based compensation under ASC 718 “Compensation – Stock Compensation”. ASC 718 requires all share-based payments to employees, including grants of employee stock options, warrants to be recognized in the consolidated financial statements based on their fair values. The Company amortizes the fair value of employee stock options on a straight-line basis over the requisite service period of the awards.  The Company accounts for equity instruments issued to non-employees as compensation in accordance with the provisions of ASC 718, which require that each such equity instrument be recorded at its fair value on the measurement date, which is typically the date the services are performed. The Black-Scholes option valuation model is used to estimate the fair value of the warrants or options granted. The Company measured the stock options issued at fair value using the Black-Scholes pricing model and are classified within Level 3 of the valuation hierarchy. The significant assumptions and valuation methods that the Company used to determine fair value and the change in fair value of the Company’s derivative financial instruments are provided below:
		17-May-13			13-Jan-14			14-May-14			14-Jul-14			1-Aug-14
	Stock price	$	0.097		$	0.17		$	0.16		$	0.17		$	0.17
	Volatility		245	%		225	%		191	%		167	%		164	%
	Risk-free interest rate		0.04	%		0.04	%		0.04	%		0.04	%		0.04	%
	Dividend yield		0			0			0			0			0
	Expected life		10 years			5 years			5 years			5 years			10 years
	In addition to the stock options issued pursuant to the 2013 stock option plan as provided above, the Company awarded 2,000,000 shares (valued at $160,000) to be provided to the CTO of the Company, to be vested over a period which is the sooner of (i) 12 months of engagement with the Company as CTO, or (ii) the successful completion of the beta test unit as specified in working with the Company’s collaborative partner, a multi-national wireless operator. Those shares became fully vested on May 1, 2014.
	The fair value of the options was determined to be as follows based upon the assumptions provided above;
	Date Issued	Number of options		Fair value
	17-May-13	4,000,000		$387,872
	13-Jan-14	4,150,000		$681,584
	14-May-14	2,000,000		$308,746
	14-Jul-14	100,000		$19,738
	1-Aug-14	2,000,000		$395,956
	The option valuations are being amortized over vesting terms ranging from immediate to 3 years. The stock commitment was amortized over a one year vesting term. For the year ended December 31, 2014, $1,628,503 (2013 –$221,643) was amortized to expense.
	Options – CelLynx Group, Inc.
	At December 31, 2014, CelLynx Group Inc. has the following Options outstanding;
		Number of Options			Weighted Average Exercise Price			Weighted Average
								Remaining Contractual
								Life (years)
	Outstanding – December 31, 2013		65,000,000			0.0002			4.3
	Cancelled		—
	Granted		4,000,000			0.0003			4.63
	Outstanding – December 31, 2014		69,000,000			0.0002			3.27
	Exercisable- December 31, 2014		69,000,000			0.0002			3.27
	Warrants – CelLynx Group, Inc.
	The following table summarizes the warrant activity to December 31, 2014:
		Number of			Weighted Average			Average Remaining
		Warrants			Exercise Price			Contractual Life
	Outstanding at December 31, 2013		4,500,000		$	0.96			0.12
	Granted		—			—			—
	Exercised		—			—			—
	Expired		—			—			—
	Outstanding at December 31, 2014		4,500,000		$	0.96			0.12
	Exercisable at December 31, 2014		4,500,000		$	0.96			0.12

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	Note 12 - Related party transactions:
	On July 8, 2014, the Company entered into a shares for debt settlement agreement with the Chairman of the Board of the Company. The parties agreed to settle $105,000 of past due consulting fees due to the Chairman of the Board for 700,000 common shares, and 700,000 warrants. Each warrant has a strike price of $0.20 and expires two years from the date of issuance, July 8, 2016.
	On July 10, 2014, the Director of Cellynx Group, Inc. was issued 100,000,000 shares of the common stock of Cellynx Group, Inc., at a cost basis of $0.0004 per share, paid as compensation for his services with a total value of $40,000. The amount is included in stock based compensation for the year ended December 31, 2014.
	On August 18, 2014, the Director of Cellynx Group, Inc. was granted 4,000,000 options of the common stock of Cellynx Group, Inc., Each option has a strike price of $0.0003 and expires five years from the date of issuance, August 18, 2019. These options were valued at $385, using the Black Scholes pricing model with a calculated volatility of 200%, and a nominal interest rate of 0.04%.

Investment_in_5BARz_AG

Investment in 5BARz AG	12 Months Ended
	Dec. 31, 2014
Investment In 5Barz Ag
Investment in 5BARz AG	Note 13 – Investment in 5BARz AG
	On October 6, 2011, the Company incorporated a subsidiary Company under the laws of Switzerland, in the Canton of Zurich, called 5BARz AG. 5BARz AG issued 10,000,000 common shares of which 5,100,000 are held by the Company, 450,000 are held by officers and a consultant to the Company and 4,450,000 were held in escrow for resale, by an independent escrow agent under the control of the Company. 5BARz AG issued the shares with a stated or par value of CHF 0.01 per share for proceeds of CHF 100,000 (US - $108,752). During the year ended December 31, 2014, sales of those securities held in escrow aggregated 11,000 shares sold for proceeds of $33,000 CHF ($36,069 USD), compared to 30,000 shares sold in 2013 for proceeds of 90,000 CHF (US - $100,710) . At December 31, 2014 the Company holds a 94.2% controlling interest in 5BArz AG represented by 9,417,000 shares.
	On October 19, 2011, the registrant, 5BARz International Inc. entered into a Marketing and Distribution agreement with 5BARz AG, through which 5BARz AG holds the exclusive rights for the marketing and distribution of products produced under the 5BARz™ brand for markets in Switzerland, Austria and Germany. That agreement does not have a royalty payment requirement, and remains effective as long as 5BARz AG is controlled by the Company. 5BARz AG is a consolidated subsidiary of the Company in these financial statements.
	In November 2014, the Company was advised that an investment banking firm (BDC Investment AG, “BDC”) involved in the financing 5BARz AG in Zurich Switzerland, was placed into liquidation by Swiss Authorities. Certain other Companies funded by BDC including 5BARz AG were also ordered to liquidate. On January 8, 2015, a communication was issued by the Swiss Authorities announcing the cessation of the liquidation of the investment banking firm. 5BARz International, Inc. is seeking a similar termination of liquidation of their subsidiary 5BARz AG. Should the liquidation not be terminated, the agreement with 5BARz AG provides for the termination of the license agreement provided to 5BARz AG. The assets of 5BARz AG were written down to zero at December 31, 2014, representing a loss of $14,583.

Investment_in_CelLynx_Group_In

Investment in CelLynx Group, Inc.	12 Months Ended
	Dec. 31, 2014
Investment In Cellynx Group Inc.
Investment in CelLynx Group, Inc.	Note 14 – Investment in CelLynx Group, Inc.
	On January 7, 2011 the Company entered into a stock purchase agreement with two founding shareholders of CelLynx Group, Inc. to acquire in aggregate 63,412,638 shares of the capital stock of CelLynx Group, Inc. for total proceeds of $634,126. At that date the Company had paid $170,000 as a deposit made under that agreement. On March 29, 2012 the Company entered into a securities exchange agreement and settlement agreement with each of the two founding shareholders of CelLynx Group, Inc. whereby in addition to the $170,000 paid, the Company issued 1,250,000 shares of its common stock in exchange for the 63,412,638 shares of CelLynx Group, Inc. and mutual releases were signed between the parties releasing each from any further obligation.
	On March 29, 2012, the Company acquired a further interest in CelLynx Group, Inc. by conversion of $73,500 of convertible debt in CelLynx Group, Inc for the issuance of 350,000,000 shares in the capital stock of CelLynx Group, Inc. As a result, in combination with the shares acquired from existing shareholders referred to above, the registrant acquired a 60% controlling interest in CelLynx Group, Inc. and has accounted for that acquisition as a consolidated subsidiary of the registrant effective March 29, 2012.
	Subsequent to that acquisition, the Company has converted amounts due, pursuant to the convertible line of credit agreement between the Company and CelLynx Group Inc. as follows;
	Date		Amount converted		Shares issued
		13-Apr-12	$	7,700		51,333,333
		15-May-12	$	58,500		390,000,000
		21-May-13	$	9,375		375,000,000
		31-Mar-14	$	26,250		105,000,000
		10-Jul-14	$	31,620		155,000,000
	Each of the conversions reflected in the preceding schedule increased the percentage ownership that the Company holds in CelLynx Group, Inc. to a 60% interest, subsequent to dilution arising from the acquisition of stock by others. At December 31, 2014 the Company had a 60% equity ownership in CelLynx Group, Inc.

Asset_Acquisition_Agreement

Asset Acquisition Agreement	12 Months Ended
	Dec. 31, 2014
Asset Acquisition Agreement
Asset Acquisition Agreement	Note 15 – Asset Acquisition Agreement
	On March 29, 2012, the Company and CelLynx Group Inc. entered into an agreement which provided several amendments to the agreement referred to above. As a result of those amendments, the following arrangements between the Companies were established;
		i.            5BARz International, Inc. acquired a 60% interest in the patents and trademarks held by CelLynx Group Inc., referred to as the “5BARz™” technology. That interest in the technology was acquired for proceeds comprised of 9,000,000 shares of the common stock of the Company, valued at the date of acquisition at $0.20 per share or $1,800,000 USD. The acquisition agreement also clarified that the ownership interest in the intellectual property does represent that proportionate interest in income earned from the intellectual property.
		ii.            The Company had agreed to make available to CelLynx Group, Inc a revolving line of credit facility as amended in the amount of $2.2 million dollars on October 5, 2010. Pursuant to this revolving line of credit facility, which was scheduled to expire on October 5, 2013, the Company advanced $2,394,643 to the date of expiry. At September 30, 2013 the Company agreed to extend the term of the line of credit facility to CelLynx Group, Inc., for the lesser of one year, or the time that CelLynx Group,Inc. becomes self sustaining from royalty income. Under the amended terms of the line of credit facility, the Company has the right to convert amounts due under the facility into common stock of CelLynx, at a conversion rate which is calculated at 51% of the average lowest three closing bid prices of the CelLynx Group, Inc. common stock for a period which is ten (10) days prior to the date of conversion. This conversion rate was established previously by other parties that have funded CelLynx, and is being matched by 5BARz. At December 31, 2014, the Company holds 1,489,745,971 shares of the capital stock of CelLynx Group, Inc. and has a balance of $ 2,865,032 principle and interest due under the line of credit facility from Cellynx Group, Inc. On September 30, 2014 the Line of Credit agreement between the parties matured. CelLynx is a consolidated subsidiary of 5BARz International Inc., since March 29, 2012.
		iii.            Pursuant to the Master Global Marketing and Distribution agreement between 5BARz International Inc and CelLynx Group, Inc., the registrant was obligated to pay to CelLynx Group, Inc a royalty fee amounting to 50% of the Company’s Net Earnings, from products or license arrangements related to the 5BARz™ technology, in a ratio equal to the CelLynx proportionate interest in the underlying technology. That fee would be paid on a quarterly basis, payable in cash or immediately available funds and shall be due and payable not later than 45 days following the end of each calendar quarter of the year. The asset acquisition agreement amendment referred to herein specified that the royalties would be paid in relation to the ownership of the intellectual property. In addition as a result of the acquisition of a 60% interest in CelLynx Group, Inc. by the registrant, this royalty item is an intercompany transaction which in the future will be eliminated upon consolidation in financial reporting of the consolidated financial results of 5BARz International Inc. and subsidiaries.

Litigation

Litigation	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Litigation	Note 16 - Litigation
	Prior to the Company’s investment in CelLynx, on July 19, 2010 certain claims for unpaid wages were filed against CelLynx, Inc. Judgments were obtained commencing in August 2011 for back wages by some of its former employees. Some of those claims have been partially paid and others were expected to be paid in the normal course of business or were to be otherwise defended. Those claims have now been incorporated into California Labor Commission awards in favor of those former employees. Those awards total approximately $263,000 depending on interest charges. It is the Company’s intention to pay these amounts. As of December 31, 2014 the Company accrued $263,000 in its financial statements.
	On September 11, 2014, a claim was filed in the District Court of Colorado against the Company claiming unpaid fees related to an investment conference held on October 5, 2012. Accredited Members, Inc. vs. 5BARz International, Inc. 14CV32449 (Arapahoe County). The claim in the amount of $9,000 alleges that 5BARz was to pay the conference fee of $4,500 by delivery of $9,000 in common shares of the Company at a price of $0.05 per share, or 180,000 shares. The Company had disputed the claim. On February 13, 2015 the action was dismissed in return for payment of 255,000 shares of 5BARz International, Inc. common stock.
	In November 2014, the Company was advised that an investment banking firm (BDC Investment AG) involved in the financing 5BARz AG in Zurich Switzerland, was placed into liquidation by Swiss Authorities, and at that time the liquidation of companies in the country that the investment banking firm had funded was also ordered. This included 5BAR AG., and accordingly that entity was placed into liquidation. On January 8, 2015, a communication was issued by FINMA, advising of the cessation of the liquidation of the investment banking firm. 5BARz International, Inc. is seeking a similar termination of liquidation of their subsidiary Company.
	In addition to the above, the Company may become involved in legal proceedings in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance.

Accounts_payable_and_accrued_l

Accounts payable and accrued liabilities	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accounts payable and accrued liabilities	Note 17 – Accounts payable and accrued liabilities
	Accounts payable and accrued expenses are comprised of the following:
		2014		2013
	Product development costs	$	556,470	$	—
	Consulting and wages		912,045		261,361
	Legal and administrative		165,587		56,471
	Acquired liabilities – CelLynx 2012		1,072,328		1,077,703
	Other		159,846		54,632
	Total	$	2,866,276	$	1,450,167

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Note 18 - Subsequent events
	Sales of Common Stock
	During the period January 1, 2015 to Mach 20, 2015 the Company issued 5,622,500 units at a price of $0.05 per unit for aggregate proceeds of $281,125. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.30 per share acquired, with a two year term on the attached warrant.
	On January 13, 2015 the Company issued 331,986 shares at a price of $0.069 per share for the settlement of convertible notes payable with a total value of $23,000. The balance of principal and interest due under this convertible note, after this conversion was $73,587.
	On February 2, 2015 the Company issued 75,000 shares at a price of $0.10 per share for services valued at $7,500 at a share price.
	On February 2, 2015 the Company issued 180,000 shares at a price of $0.05 per share in settlement of accrued payables of $9,000.
	On February 20, 2015 the Company issued 180,000 shares for services at a price of $0.05 per share an aggregate amount of $9,000.
	Convertible Note Agreements
	On March 3, 2015 the Company entered into a convertible note arrangement with an investment Company, in the principle amount of $350,000 of which $175,000 was advanced to the Company at the inception of the note. The Company agreed to pay an “original issue discount” in an amount up to 10% of the loan amount, or $17,500. The loan may be repaid at any time during the first six months of the note term, at a prepayment premium on day 90 of 115%, increasing by 5% each month to month 6. After month three, if the note is not repaid, a one time interest charge of 10% will be assessed. After 6 months, the note is convertible into common stock of the issuer at a discount to market of 35%, with the market defined as the lowest trade price for a period of 25 days prior to the conversion, with a conversion floor price at no lower than $0.001.
	On March 6, 2015 the Company entered into a Note and Warrant adjustment purchase agreement with two parties who have agreed to provide to the Company additional resources to run operations. The parties have agreed to loan $400,000 pursuant to the terms of a convertible promissory note and warrant adjustment agreement. On the closing date, March 6, 2015 the Company received $400,000 cash. The note matures on September 6, 2015. The loan maturity may be extended for an additional 6 months by payment on the original maturity date of unpaid interest, plus a 10% extension fee. The convertible note accrues interest at a rate of 15% semi annually and provides for the conversion of the principle and accrued interest on the note into common stock at any time, at the election of the holder at a price of $0.05 per share. Further, warrants to acquire up to 12,441,667 shares which had been issued in conjunction with previous financings at strike prices ranging from $0.20 to $0.30 per share, are to be re-priced to a strike price of $0.05 per share with the maturity dates changed to March 6, 2016. The Company has the right to repay the loan by payment of the principle and accrued interest at the date of repayment.
	Incorporation of Subsidiary Companies
	On January  12, 2015, 5BARz International, Inc. incorporated another subsidiary Company, 5BARz International, SA DE CV in Mexico. The Company is a 99% owned subsidiary of 5BARz International, Inc. with the remaining 1% owned by Daniel Bland, the CEO of 5BARz International, Inc. The Company has obtained the necessary product approvals for the sale of the 5BARz Road Warrior product in Mexico, and has imported a limited inventory of product for resale in the Country.
	On January 12, 2015, 5Barz India Private Limited was incorporated in India, a 99.9% subsidiary of 5BARz International, Inc. The Company has delivered prototype products to India in December 2014, and that product is experiencing very positive test results in the country. The Company has developed interest in the product from Tier 1 cellular network operators in the region, with testing programs in process.

Summary_of_significant_account1

Summary of significant accounting policies (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Basis of Presentation

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles generally accepted in the United States of America

The accompanying consolidated financial statements include the accounts of 5BARz International Inc., and its 94.2% owned subsidiary, 5BARz AG, and it’s 60% owned subsidiary CelLynx Group, Inc. and that Company’s 100% owned subsidiary CelLynx, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

As the Company has not yet commenced any revenue-generating operations, does not have any cash flows from operations, and is dependent on debt and equity funding to finance its operations, the Company is considered a development stage company. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to commercialize the Company’s current technology before another company develops similar technology.

In June 2014, as discussed in Note, 2, the Financial Accounting Standards Board issued new guidance that removed all incremental financial reporting requirements from generally accepted accounting principles in the United States for development stage entities. The Company early adopted this new guidance effective June 30, 2014, as a result of which all inception-to-date financial information and disclosures have been removed from this report.

Cash

Cash

Cash and cash equivalents include cash in hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of one year or less.

Use of estimates

Use of estimates

The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include impairment analysis for long lived assets, income taxes, litigation and valuation of derivative instruments. Actual results could differ from those estimates.

Concentration of credit risk

Concentration of credit risk

Cash includes deposits in accounts maintained at financial institutions.  Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash. The Company maintains balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits for the banks located in the United States. To date, the Company has not experienced any losses in such accounts.

Research and development costs

Research and development costs

Research and development costs are charged to expense as incurred. The costs of materials and equipment that are required or constructed for research and development activities, and have alternative future uses (either in research and development, marketing or production), are classified as property and equipment and depreciated over their estimated useful lives.

Furniture and Equipment

Furniture and equipment

Furniture & equipment is recorded at historical cost and is depreciated using the straight-line method over their estimated useful lives. Leasehold improvements are being amortized over the shorter of the useful life or the remaining lease term.  The useful life and depreciation method are reviewed periodically to ensure that the depreciation method and period are consistent with the anticipated pattern of future economic benefits. Expenditures for maintenance and repairs are charged to operations as incurred while renewals and betterments are capitalized. Gains and losses on disposals are included in the results of operations. The useful life of the equipment is being depreciated over three to seven years.

Inventory

Inventory

Inventories are carried at the lower of cost and net realizable value. Cost is determined using the weighted-average method.   As of December 31, 2014 the Company’s inventory included 988 units of Road Warrior cellular networks extenders.

Goodwill and other intangible assets

Goodwill and other intangible assets

The Company accounts for goodwill and intangible assets in accordance with the accounting guidance which requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. The Accounting Standards Codification (“Codification”) requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment). Application of the goodwill impairment test requires judgment, including the identification of reporting units, assigning assets and liabilities to reporting units, assigning goodwill to reporting units, and determining the fair value. Significant judgment is required to estimate the fair value of reporting units which includes estimating future cash flows, determining appropriate discount rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value and/or goodwill impairment.

When testing goodwill for impairment, the Company may assess qualitative factors for some or all of its reporting units to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment for some or all of our reporting units and perform a detailed quantitative test of impairment (step 1). If the Company performs the detailed quantitative impairment test and the carrying amount of the reporting unit exceeds its fair value, the Company would perform an analysis (step 2) to measure such impairment. In 2013, the Company first performed a qualitative assessment to identify and evaluate events and circumstances to conclude whether it is more likely than not that the fair value of the Company’s reporting unit is less than its carrying amount. Based on the Company’s qualitative assessments, the Company concluded that a positive assertion can be made from the qualitative assessment that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount. In accordance with the Codification, the Company reviews the carrying value of its intangibles and other long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group, if any, exceeds its fair market value. No impairment was deemed to exist as of December 31, 2014 and 2013.

Long-Lived Assets Subject to Amortization

Long-Lived Assets Subject to Amortization

The Company amortizes intangible assets with finite lives over their estimated useful lives and reviews them for impairment annually or whenever an impairment exists. The Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. There were no long-lived assets impairment charges recorded during the years ended December 31, 2014 and 2013.

Revenue recognition

Revenue recognition

The Company's revenue recognition policies are in compliance with ASC Topic 605, “Revenue Recognition.”  Revenue is recognized at the date of shipment to customers, and when the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured.

Foreign currency translation

Foreign currency translation

Transactions in foreign currencies have been translated into US dollars using the temporal method. The functional currency of the Company’s subsidiary 5BARz AG, is its local currency (Swiss Franc – CHF). Under this method, monetary assets and liabilities are translated at the year-end exchange rate. Non-monetary assets have been translated at the historical rate of exchange prevailing at the date of the transaction. Expenses have been translated at the exchange rate at the time of the transaction. Realized and unrealized foreign exchange gains and losses are included in operations.

Fair value of financial instruments

Fair value of financial instruments

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities, approximate fair value due to the short-term nature of these instruments.

Fair value is defined as an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:

•

Level 1. Quoted prices in active markets for identical assets or liabilities.

•

Level 2. Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.

•

Level 3. Significant unobservable inputs that cannot be corroborated by market data.

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the assets that are measured at fair value on a recurring basis.

Consolidated

Quoted Prices in Active Markets for Identical Assets or Liabilities

Quoted Prices for Similar Assets or Liabilities in Active Markets

Significant

Balance Sheet

(Level 1)

(Level 2)

Unobservable

Inputs

(Level 3)

Derivative Liabilities:

31-Dec-14

$

547,940

$

—

$

—

$

547,940

31-Dec-13

$

60,018

$

—

$

—

$

60,018

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:

31-Dec-14

31-Dec-13

Beginning balance

$

60,018

$

—

Aggregate fair value of conversion feature upon issuance

245,490

57,995

Change in fair value of derivative liabilities

242,432

2,023

Ending balance

$

547,940

$

60,018

The derivative conversion feature liabilities are measured at fair value using the Black-Scholes pricing model and are classified within Level 3 of the valuation hierarchy. The significant assumptions and valuation methods that the Company used to determine fair value and the change in fair value of the Company’s derivative financial instruments are provided below:

31-Dec-14

31-Dec-13

Stock price

$

0.11

$

0.25

Volatility

83

%

211

%

Risk-free interest rate

0.46

%

0.04

%

Dividend yield

0

%

0

%

Expected life

1.63 years

0.002 years

Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivate liabilities. For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, which reports to the Chief Financial Officer, determines its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department with support from the Company’s consultants and which are approved by the Chief Financial Officer.

Level 3 financial liabilities consist of the derivative liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.

The Company uses the Black-Scholes option valuation model to value Level 3 financial liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as, volatility.

As of December 31, 2014 there were no transfers in or out of Level 3 from other levels in the fair value hierarchy.

Derivative Instruments

Derivative Instruments

The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging”. The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liability at the fair value of the instrument on the reclassification date.

Stock-based Compensation

Stock-Based Compensation

The Company records stock-based compensation in accordance with ASC Topic 718, “Compensation – Stock Compensation.” ASC 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the employee’s requisite service period. Under ASC 718, the Company’s volatility is based on the historical volatility of the Company’s stock or the expected volatility of similar companies. The expected life assumption is primarily based on historical exercise patterns and employee post-vesting termination behavior. The risk-free interest rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant.

The Company uses the Black-Scholes option-pricing model which was developed for use in estimating the fair value of options. Option-pricing models require the input of highly complex and subjective variables including the expected life of options granted and the Company’s expected stock price volatility over a period equal to or greater than the expected life of the options. Because changes in the subjective assumptions can materially affect the estimated value of the Company’s employee stock options, it is management’s opinion that the Black-Scholes option-pricing model may not provide an accurate measure of the fair value of the Company’s employee stock options. Although the fair value of employee stock options is determined in accordance with ASC 718 using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/seller market transaction.

The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

The Company incurred stock based compensation charges during the year ended December 31, 2014 and 2013 as follows;

Year ended

31-Dec

2014

2013

General and administrative

$

750,712

$

436,958

Research and development

452,427

164,155

Sales and marketing

425,364

—

Total

$

1,628,503

$

601,113

Income Taxes

Income taxes

The Company accounts for income taxes in accordance with ASC Topic 740, “Income Taxes.” ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized.  Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Net loss per share

Net loss per share

The Company reports loss per share in accordance with the ASC Topic 260, “Earnings Per Share.”, which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation.  In the accompanying financial statements, basic earnings per share of common stock is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants. These potentially dilutive securities of 102,517,763 and 49,855,171, respectively were not included in the calculation of loss per common share for the years ended December 31, 2014 or 2013 because their effect would be anti-dilutive. The weighted average number of shares outstanding does not include reciprocal shareholdings, held by the Company’s subsidiary, CelLynx Group, Inc. which is reflected as a reduction in capital in excess of par value on the Company’s balance sheet.

Recent accounting pronouncements

Recent Accounting Pronouncements

In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation." This ASU removes the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the ASU eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. This ASU is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company has elected to adopt this ASU effective with the June 30, 2014 Quarterly Report on Form 10-Q and its adoption resulted in the removal of previously required development stage disclosures.

In June 2014, the FASB issued ASU No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We do not anticipate that the adoption of this standard will have a material impact on our consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this ASU provide that guidance. In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures.

The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for public and nonpublic entities for annual periods ending after December 15, 2016. Early adoption is permitted. The Company has elected to adopt this ASU effective with this Annual Report on Form 10-K and its adoption resulted in the additional disclosures in Note 1, reflecting management’s assessment of the mitigating effect of management’s plans on the Company’s ability to continue as a going concern.

FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2014 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2014 or 2013, and it does not believe that any of those pronouncements will have a significant impact on our consolidated financial statements at the time they become effective.

Reclassifications

Reclassifications

Certain prior year amounts have been reclassified to conform to the current presentation. The reclassification did not have any effect on the reported consolidated net losses for any periods presented.

Summary_of_Accounting_Policies

Summary of Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Fair Value of Financial instruments Assets and Liabilities		Consolidated			Quoted Prices in Active Markets for Identical Assets or Liabilities			Quoted Prices for Similar Assets or Liabilities in Active Markets		Significant
		Balance Sheet			(Level 1)			(Level 2)		Unobservable
										Inputs
										(Level 3)
	Derivative Liabilities:
	31-Dec-14	$	547,940		$	—		$	—	$	547,940
	31-Dec-13	$	60,018		$	—		$	—	$	60,018
Level 3 financial liabilities that are measured at fair value on a recurring basis
		31-Dec-14			31-Dec-13
	Beginning balance	$	60,018		$	—
	Aggregate fair value of conversion feature upon issuance		263,490			57,995
	Change in fair value of derivative liabilities		224,432			2,023
	Ending balance	$	547,940		$	60,018
Fair Value of Financial instruments Black-Scholes option pricing models		31-Dec-14			31-Dec-13
	Stock price	$	0.11		$	0.25
	Volatility		83	%		211	%
	Risk-free interest rate		0.46	%		0.04	%
	Dividend yield		0	%		0	%
	Expected life		1.63 years			0.002 years
Stock Compensation Changes
		Year ended
		31-Dec
		2014			2013
	General and administrative	$	798,885		$	436,958
	Research and development		452,427			164,155
	Sales and marketing		425,364			—
	Total	$	1,676,676		$	601,113

Furniture_Equipment_Tables

Furniture & Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Furniture & Equipment
		31-Dec-14			31-Dec-13
	Office furniture and equipment	$	137,148		$	70,804
	Research and development equipment (i)		169,350			169,350
	Leasehold improvements		46,318			6,940
			352,816			247,094
	Accumulated amortization and depreciation		(90,461	)		(21,111	)
	Furniture and equipment, net	$	262,355		$	225,983

Long_lived_assets_and_goodwill

Long lived assets and goodwill subject to amortization (Tables)	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Intangible Assets			31-Dec-14				31-Dec-13
	Technology		$	3,067,827			$	3,015,794
	Marketing and distribution agreement			370,000				370,000
	Trademarks			264				264
	License rights			1,348				1,348
				3,439,439				3,387,406
	Accumulated amortization			(203,406	)			—
	Technology and other intangibles, net		$	3,236,033			$	3,387,406
Estimated amortization of intangible assets	For the years ended				Total				Technology		Marketing and
	December 31,										distribution agreement		Trademark & license
													agreements
		2015			$	491,441			$	438,261	$	52,857	$	323
		2016				491,440				438,261		52,857		322
		2017				491,440				438,261		52,857		322
		2018				491,440				438,261		52,857		322
		2019				491,119				438,262		52,857		0
		Future years				779,153				695,462		83,691		0
					$	3,236,033			$	2,886,768	$	347,976	$	1,289

Goodwill_Tables

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill		31-Dec-14		31-Dec-13
	Goodwill – beginning of year	$	1,140,246	$	1,140,246
	Goodwill – end of year	$	1,140,246	$	1,140,246

Income_taxes_Tables

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Domestic and Foreign components of income (loss) before income taxes
		31-Dec-14			31-Dec-13
	Domestic	$	(9,622,324	)	$	(2,251,545	)
	Foreign		(117,912	)		(45,055	)
	Loss from continuing operations before provision for income taxes	$	(9,740,236	)	$	(2,296,600	)
Income tax provision (benefit)
		31-Dec-14			31-Dec-13
	Foreign
	Current	$	0		$	0
	Deferred		(25,941	)		(9,912	)
	U.S. federal
	Current		0			0
	Deferred		(2,897,734	)		(604,970	)
	State & local
	Current		0			0
	Deferred		(30,938	)		(214,066	)
	Total		(2,954,613	)		(828,948	)
	Change in valuation allowance		2,954,613			828,948
	Income tax provision (benefit)	$	0		$	0
Reconciliation of statutory and effective income tax rate
		31-Dec-14			31-Dec-13
	U.S. federal statutory income tax rate (benefit)		(34.0	%)		(34.0	%)
	State income taxes		(0.4	%)		(5.8	%)
	Stock based compensation		0	%		10.4	%
	Other permanent differences		4.1	%		1.5	%
	Change in valuation allowance		30.3	%		27.9	%
	Effective rate		0	%		0	%
Deferred Tax asset and liability
		31-Dec-14			31-Dec-13
	Deferred tax assets
	Net operating loss carryovers	$	4,466,003		$	2,077,660
	R&D credit		321,482			66,017
	Accrued compensation		37,796			202,375
	Stock-based compensation		358,762			2,833
	Derivative liability		76,739			0
	Total deferred tax assets		5,260,782			2,348,886
	Valuation allowance		(5,117,872	)		(2,163,259	)
	Deferred tax asset, net of valuation allowance		142,910			185,626
	Deferred tax liabilities
	Fixed asset depreciation		(11,347	)		(14,024	)
	Intangible asset amortization		(54,824	)		(171,602	)
	Convertible debt		(76,739	)		0
	Total deferred tax liabilities		(142,910	)		(185,626	)
	Net deferred tax asset (liability)	$	0		$	0

Notes_payable_Tables

Notes payable (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Convertible Promissory Note
	5BARz International, Inc.	Unpaid		Note	Unpaid		Balance			Balance
		Note Principal		Terms	Interest		31-Dec-14			31-Dec-13
	Issue Date
	3-Feb-12		—	(a)		—		—			103,997
	17-Dec-12		80,000	(b)		13,045		93,045			86,645
	8-Jan-13		96,313	(c)				96,313			154,017
	21-Aug-14		150,000	(d)		34,667		184,667			—
	6-Oct-14		250,000	(e)		623		250,623
	Notes payable – 5BARz International Inc.	$	576,313		$	48,335	$	624,648		$	344,659
	CelLynx Group Inc.
	24-May-12		15,900	(f)		21,248		37,148			37,822
	12-Sep-12		12,500	(g)		14,176		26,676			27,702
	Notes payable CelLynx Group, Inc.	$	28,400		$	35,424	$	63,824		$	65,524
	Sub-Total	$	604,713		$	83,759	$	688,472		$	410,183
	Debt Discount		—			—		(407,986	)		—
	Total, net of debt discount	$	604,713		$	83,760	$	280,486		$	410,183

Captial_Lease_Obligation_Table

Captial Lease Obligation (Tables)	12 Months Ended
	Dec. 31, 2014
Captial Lease Obligation Tables
Capital Lease Minimum Lease Payments		2015	$	75,000
		2016	$	50,000
		Total	$	125,000
		Interest (12%)	$	(4,094	)
		Capitalized valuation of equipment	$	120,906
Operating Lease Minimum Lease Payments
		2015	$	219,772
		2016	$	264,314
		2017	$	290,788
		2018	$	300,966
		2019	$	311,499
		Aggregate over 5 years	$	53,380
		Total	$	1,440,719

Options_and_Warrants_Tables

Options and Warrants (Tables)	12 Months Ended
	Dec. 31, 2014
Options And Warrants Tables
Warrants - 5BARz International Inc.		Number of			Weighted Average			Average Remaining
		Warrants			Exercise Price			Contractual Life
	Outstanding at December 31, 2013		47,580,103		$	0.26			1.64
	Granted*		34,920,294		$	0.28
	Exercised		—			—
	Cancelled		(540,000	)	$	0.2
	Outstanding at December 31, 2014		81,960,397		$	0.28			0.98
	Exercisable at December 31, 2014		81,960,397		$	0.28			0.98
Options- 5BARz International Inc.		Number of Options			Weighted Average Exercise Price			Weighted Average
								Remaining Contractual
								Life (years)
	Outstanding – December 31, 2013		4,000,000			0.1			8.38
	Granted		8,250,000			0.17			5.37
	Outstanding – December 31, 2014		12,250,000			0.15			6.42
	Exercisable- December 31, 2014		12,250,000			0.15			6.42
Significant Assumptions and valuation methods - 5BARz International Inc.
		17-May-13			13-Jan-14			14-May-14			14-Jul-14			1-Aug-14
	Stock price	$	0.097		$	0.17		$	0.16		$	0.17		$	0.17
	Volatility		245	%		225	%		191	%		167	%		164	%
	Risk-free interest rate		0.04	%		0.04	%		0.04	%		0.04	%		0.04	%
	Dividend yield		0			0			0			0			0
	Expected life		10 years			5 years			5 years			5 years			10 years
Fair Value of options	Date Issued	Number of options		Fair value
	17-May-13	4,000,000		$387,872
	13-Jan-14	4,150,000		$681,584
	14-May-14	2,000,000		$308,746
	14-Jul-14	100,000		$19,738
	1-Aug-14	2,000,000		$395,956
Options-CelLynx Group, Inc.		Number of Options			Weighted Average Exercise Price			Weighted Average
								Remaining Contractual
								Life (years)
	Outstanding – December 31, 2013		65,000,000			0.0002			4.3
	Cancelled		—
	Granted		4,000,000			0.0003			4.63
	Outstanding – December 31, 2014		69,000,000			0.0002			3.27
	Exercisable- December 31, 2014		69,000,000			0.0002			3.27
Warrants - CelLynx Group, Inc.
		Number of			Weighted Average			Average Remaining
		Warrants			Exercise Price			Contractual Life
	Outstanding at December 31, 2013		4,500,000		$	0.96			0.12
	Granted		—			—			—
	Exercised		—			—			—
	Expired		—			—			—
	Outstanding at December 31, 2014		4,500,000		$	0.96			0.12
	Exercisable at December 31, 2014		4,500,000		$	0.96			0.12

Accounts_payable_and_accrued_l1

Accounts payable and accrued liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accounts payable and accrued expenses
		2014		2013
	Product development costs	$	556,470	$	—
	Consulting and wages		912,045		261,361
	Legal and administrative		165,587		56,471
	Acquired liabilities – CelLynx 2012		1,072,328		1,077,703
	Other		159,846		54,632
	Total	$	2,866,276	$	1,450,167

Organization_Details

Organization (Details)	12 Months Ended	9 Months Ended
	Dec. 31, 2014	Sep. 30, 2012	Dec. 31, 2013
5BARz AG
Business Acquisition [Line Items]
Agreement date	6-Nov-11
Acquired interest	94.20%		94.20%
Percentage Owned	60.00%
Cellynx Group, Inc.
Business Acquisition [Line Items]
Agreement date		29-Mar-12
Ownership in Entity		CeLlynx Inc.
Percentage Owned		100.00%

Going_concern_Details

Going concern (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Going Concern Details
Net (loss) before non-controlling interest	($9,740,236)	($2,296,600)
Net cash from used in operating activities	-5,440,416	-2,230,355
Gross proceeds from private placements	$4,840,545	$2,930,750
Increase in private placement	65.00%

Summary_of_Accounting_Policies1

Summary of Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Net loss per share
Dilutive securities	102,517,763	49,855,171
Level 3
AccountingPoliciesLineItems [Line Items]
Derivative Liabilities	60,018
Aggregate fair value of conversion feature upon issuance	263,490	57,995
Change in fair value of derivative liabilities	224,432	2,023
Derivative Liabilities	547,940	60,018
Level 3 Valuation Methodolgy
Stock Price	0.11	0.25
Expected volatility	83.00%	211.00%
Risk-free Interest	0.46%	0.04%
Annual Dividend Yield	0.00%	0.00%
Exepected Life (years)	1 year 6 months 3 days	2 days

Summary_of_Accounting_Policies2

Summary of Accounting Policies -Stock based compensation (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock based compensation expense	$1,676,676	$601,113
General and administration
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock based compensation expense	798,885	436,958
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock based compensation expense	452,427	164,155
Selling and marketing
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock based compensation expense	$425,364

Equipment_Details_Narrative

Equipment (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and Equipment	$352,816	$247,094
Accumulated depreciation	-90,461	-21,111
Furniture & equipment net	262,355	225,983
Office furniture and equipemnt
Property, Plant and Equipment [Line Items]
Property and Equipment	137,148	70,804
Research and development equipment
Property, Plant and Equipment [Line Items]
Property and Equipment	169,350	169,350
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and Equipment	$46,318	$6,940

Equipment_Additional_Details_N

Equipment Additional (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Equipment Additional Details Narrative
Depreciation Expense	$79,230	$10,985

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$3,439,439	$3,387,406
Accumulated amortization	-203,406
Intangibles Assets, net	3,236,033	3,387,406
Technology
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	3,067,827	3,015,794
Marketing and distribution Agreement
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	370,000	370,000
Trademark and license agreement
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	264	264
License rights
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$1,348	$1,348

Intangible_Assets_Details_Narr

Intangible Assets (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Estimated Amortization-2015	$491,441
Estimated Amortization-2016	491,440
Estimated Amortization-2017	491,440
Estimated Amortization-2018	491,440
Estimated Amortization-2019	491,119
Estimated Amortization- Future years	779,153
Total Estimated Amortization	3,236,033
Patented and unpatented technology
Finite-Lived Intangible Assets [Line Items]
Life of amortization	5 years
Total Estimated Amortization	2,191,306
Amortization Expense	203,406
Technology
Finite-Lived Intangible Assets [Line Items]
Estimated Amortization-2015	438,261
Estimated Amortization-2016	491,440
Estimated Amortization-2017	491,440
Estimated Amortization-2018	491,440
Estimated Amortization-2019	491,119
Estimated Amortization- Future years	779,153
Total Estimated Amortization	3,236,033
Marketing and distribution Agreement
Finite-Lived Intangible Assets [Line Items]
Estimated Amortization-2015	52,857
Estimated Amortization-2016	52,857
Estimated Amortization-2017	52,857
Estimated Amortization-2018	52,857
Estimated Amortization-2019	52,857
Estimated Amortization- Future years	83,691
Total Estimated Amortization	2,886,768
Trademark and license agreement
Finite-Lived Intangible Assets [Line Items]
Estimated Amortization-2015	323
Estimated Amortization-2016	322
Estimated Amortization-2017	322
Estimated Amortization-2018	322
Estimated Amortization-2019	0
Estimated Amortization- Future years	0
Total Estimated Amortization	$1,289

Goodwill_Details_Narrative_USD

Goodwill (Details Narrative) (USD $) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$1,140,246	$1,140,246

Components_of_income_taxes_Det

Components of income taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Domestic	($9,622,324)	($2,251,545)
Foreign	-117,912	-45,055
Loss from continuing operation before provision for income taxes	($9,740,236)	($2,296,600)

Income_Tax_Provision_benefit_D

Income Tax Provision (benefit) (Details) (USD $) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Foreign
Current	$0	$0
Deferred	-25,941	-9,912
US federal
Current	0	0
Deferred	-2,897,734	-604,970
State & local
Current	0	0
Deferred	-30,938	-214,066
Total	-2,954,613	-828,948
Change in valuation allowance	2,954,613	828,948
Income tax provision (benefit)	$0	$0

Reconciliation_of_statutory_an

Reconciliation of statutory and effective income tax rate (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
US federal statutory income tax rate (benefit)	-34.00%	-34.00%
State income taxes	-0.40%	-5.80%
Stock based compensation	0.00%	10.40%
Other permanent differences	4.10%	1.50%
Change in valuation allowance	30.30%	27.90%
Effective rate	0.00%	0.00%

Deferred_Tax_asset_and_liabili

Deferred Tax asset and liability (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carry-forwards	$4,466,003	$2,077,660
R&D credit	321,482	66,017
Accrued compensation	37,796	202,375
Stock-based compensation	358,762	2,833
Derivative liability	76,739	0
Total deferred tax assets	5,260,782	2,348,886
Valuation allowance	-5,117,872	-2,163,259
Deferred tax asset, net of valuation allowance	142,910	185,626
Deferred tax liabilities
Fixed asset depreciation	-11,347	-14,024
Intangible asset amortization	-54,824	-171,602
Convertible debt	-76,739	0
Total deferred tax liabilities	-142,910	-185,626
Net deferred tax assets (liability)	$0	$0

Federal_income_tax_Details_Nar

Federal income tax (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
US Federal net operating loss	$12,757,884	$12,757,000
State net operating loss	5,398,527	5,398,527
Cellynx net operating loss annual limitation	8,700
Cellynx net operating loss	8,600,000
Swiss net operating loss carryovers	372,780	254,868
Change in valuation allowance	$2,954,613	$828,948

Cumulative_Sales_of_Stock_2013

Cumulative Sales of Stock 2013 (Details) (USD $)	0 Months Ended																													1 Months Ended	4 Months Ended		12 Months Ended
	Nov. 14, 2014	Nov. 01, 2014	Oct. 02, 2014	Sep. 15, 2014	Jul. 16, 2014	Jul. 08, 2014	29-May-14	1-May-14	Mar. 05, 2014	Feb. 10, 2014	Jan. 15, 2014	Dec. 31, 2013		Nov. 15, 2013	Jul. 03, 2013		Jun. 30, 2013	28-May-13	23-May-13	15-May-13	Apr. 10, 2013	Apr. 02, 2013	Mar. 31, 2013	Mar. 17, 2013	Mar. 01, 2013	Feb. 26, 2013	Feb. 15, 2013	Feb. 12, 2013	Jan. 25, 2013	Dec. 31, 2014	Sep. 30, 2014	Nov. 18, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 06, 2014
Class of Stock [Line Items]
Issuance of common stock																																	$4,840,545	$2,930,750
Stock Issued During Period																																	105,000	772,441
Common Stock
Class of Stock [Line Items]
Stock issued			25,000					2,000,000				740,000	[1]					100,000		200,000	600,000				600,000
Units Issued (in shares)	23,103,632			325,000					6,550,000										200,000			425,000								14,400,000			14,400,000		29,215,000
Issuance of common stock			4,250					160,000									586,750	50,000	10,000	10,000	30,000	21,250			30,000								44,054	35,775
Common stock issued for services (in shares)		25,000			11,400					405,581		14,350,000	[1]		331,200	[1]							100,000	513,827	175,000		14,400,000		100,000		200,000
Common stock issued for services		3,500		48,750	570					100,000		71,750			66,240								5,000	25,691	8,750		72,000		5,000		40,250			3,581
Common stock issued for debt, shares						700,000	347,222				100,000			25,000												250,000		125,000					700,000	8,689,710
Stock Issued During Period						105,000	50,000				16,700															10,000		7,500					700	8,690
Price Per Unit	$0.30	$0.14	$0.17	$0.30	$0.05	$0.15	$0.14		$0.30	$0.25	$0.17	$0.20		$0.20	$0.20			$0.05		$0.05	$0.05		$0.05	$0.05	$0.05	$0.04		$0.06		$0.30	$0.20	$0.10	$0.30	$0.20	$0.10
Warrant price	0.15			0.15		0.2			0.1			0.3							0.2			0.2	0.2							0.05		0.3	0.05	0.3	0.3
Cash received for issuance of stock	3,465,545								655,000																					720,000		6,044,103
Settlement of debt for common stock												74,000		5,000																		604,411
Common Stock Additional
Class of Stock [Line Items]
Common stock issued for services (in shares)																										91,780
Common stock issued for services																										$4,589
Price Per Unit																										$0.05
[1]	Each unit is comprised of one share and one warrant to acquire a second share, with a two year warrant term.

Cumulative_Sales_of_Stock_2014

Cumulative Sales of Stock 2014 (Details) (USD $) (USD $)	0 Months Ended																													1 Months Ended	4 Months Ended		12 Months Ended
	Nov. 14, 2014	Nov. 01, 2014	Oct. 02, 2014	Sep. 15, 2014	Jul. 16, 2014	Jul. 08, 2014	29-May-14	1-May-14	Mar. 05, 2014	Feb. 10, 2014	Jan. 15, 2014	Dec. 31, 2013		Nov. 15, 2013	Jul. 03, 2013		Jun. 30, 2013	28-May-13	23-May-13	15-May-13	Apr. 10, 2013	Apr. 02, 2013	Mar. 31, 2013	Mar. 17, 2013	Mar. 01, 2013	Feb. 26, 2013	Feb. 15, 2013	Feb. 12, 2013	Jan. 25, 2013	Dec. 31, 2014	Sep. 30, 2014	Nov. 18, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 06, 2014
Class of Stock [Line Items]
Issuance of common stock																																	$4,840,545	$2,930,750
Stock Issued During Period, other (value)																																	105,000	772,441
Common Stock
Class of Stock [Line Items]
Units Issued (in shares)	23,103,632			325,000					6,550,000										200,000			425,000								14,400,000			14,400,000		29,215,000
Issuance of common stock (in shares)			25,000					2,000,000				740,000	[1]					100,000		200,000	600,000				600,000
Issuance of common stock			4,250					160,000									586,750	50,000	10,000	10,000	30,000	21,250			30,000								44,054	35,775
Common stock issued for services (in shares)		25,000			11,400					405,581		14,350,000	[1]		331,200	[1]							100,000	513,827	175,000		14,400,000		100,000		200,000
Common stock issued for services		3,500		48,750	570					100,000		71,750			66,240								5,000	25,691	8,750		72,000		5,000		40,250			3,581
Common stock issued for debt, shares						700,000	347,222				100,000			25,000												250,000		125,000					700,000	8,689,710
Stock Issued During Period, other (value)						105,000	50,000				16,700															10,000		7,500					700	8,690
Price Per Unit	$0.30	$0.14	$0.17	$0.30	$0.05	$0.15	$0.14		$0.30	$0.25	$0.17	$0.20		$0.20	$0.20			$0.05		$0.05	$0.05		$0.05	$0.05	$0.05	$0.04		$0.06		$0.30	$0.20	$0.10	$0.30	$0.20	$0.10
Warrant price	0.15			0.15		0.2			0.1			0.3							0.2			0.2	0.2							0.05		0.3	0.05	0.3	0.3
Cash received for issuance of stock	3,465,545								655,000																					720,000		6,044,103
Common Stock Additional
Class of Stock [Line Items]
Common stock issued for services (in shares)										1,250,000
Common stock issued for services										$287,500
Price Per Unit										$0.23
[1]	Each unit is comprised of one share and one warrant to acquire a second share, with a two year warrant term.

Convertible_Promissory_Notes_D

Convertible Promissory Notes (Details) (USD $) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Debt Conversion [Line Items]
Unpaid Note Principal	$604,713
Unpaid Interest & penalty	83,759
Notes Payable	688,472	410,183
Debt discount	-407,986
Notes payable, net of debt discount	280,486	410,183
Note a
Debt Conversion [Line Items]
Issue Date	3-Feb-12
Unpaid Interest & penalty
Notes Payable		103,997
Note b
Debt Conversion [Line Items]
Issue Date	17-Dec-12
Unpaid Note Principal	80,000
Unpaid Interest & penalty	13,045
Notes Payable	93,045	86,645
Note c
Debt Conversion [Line Items]
Issue Date	8-Jan-13
Unpaid Note Principal	96,313
Notes Payable	96,313	154,017
Note d
Debt Conversion [Line Items]
Issue Date	21-Aug-14
Unpaid Note Principal	150,000
Unpaid Interest & penalty	34,667
Notes Payable	184,667
Note e
Debt Conversion [Line Items]
Issue Date	16-Oct-14
Unpaid Note Principal	250,000
Unpaid Interest & penalty	623
Notes Payable	250,623
5BARz
Debt Conversion [Line Items]
Unpaid Note Principal	576,313
Unpaid Interest & penalty	48,335
Notes Payable	624,648	344,659
Note f
Debt Conversion [Line Items]
Issue Date	24-May-12
Unpaid Note Principal	15,900
Unpaid Interest & penalty	21,248
Notes Payable	37,148	37,822
Note g
Debt Conversion [Line Items]
Issue Date	2-Sep-12
Unpaid Note Principal	12,500
Unpaid Interest & penalty	14,176
Notes Payable	26,676	27,702
Notes Payable Cellynx Group Inc.
Debt Conversion [Line Items]
Unpaid Note Principal	28,400
Unpaid Interest & penalty	35,424
Notes Payable	$63,824	$65,524

Convertible_Promissory_Notes_D1

Convertible Promissory Notes (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Debt Conversion [Line Items]
Issuance of common stock	$4,840,545	$2,930,750
Principal Amount	604,713
Shares issued for Debt, amount	105,000	772,441
Note Payable	688,472	410,183
Note a
Debt Conversion [Line Items]
Issue Date	3-Feb-12
Proceeds from Covertible debenture	100,000
Additional Proceeds	50,000
Common stock issued for debt, shares	125,000
Shares issued for Debt, amount	300,000
Aggregate payments	325,939
Note Payable		103,997
Convertible Debenture Agreement	500,000
Alleged damages	2,500,000
Investment of purchase of common stock	150,000
Note b
Debt Conversion [Line Items]
Issue Date	17-Dec-12
Issuance of common stock (in shares)	1,600,000
Issuance of common stock	80,000
Principal Amount	80,000
Interest Rate per annum	8.00%
Discount percentage	0.2
Price per share	$0.05
Accrued interest	13,045
Note Payable	93,045	86,645
Derivative Liability	23,262
Note c
Debt Conversion [Line Items]
Issue Date	8-Jan-13
Principal Amount	96,313
Interest Rate per annum	8.00%
Discount percentage	0.2
Price per share	$0.05
Shares issued for Debt, amount	147,428
Accrued interest	20,584
Note Payable	96,313	154,017
Convertible Debenture Agreement	66,700
Convertible Debenture Agreement, purchase of Common stock	5,000
Derivative Liability	24,079
Note d
Debt Conversion [Line Items]
Issue Date	21-Aug-14
Proceeds from Covertible debenture	500,000
Principal Amount	150,000
Interest Rate per annum	12.00%
Discount percentage	0.1
Original Issue Discount	16,667
Price per share	$0.00
Note balance payoff	186,667
Accrued interest	18,000
Note Payable	184,667
Derivative Liability	500,599
Note e
Debt Conversion [Line Items]
Issue Date	16-Oct-14
Additional Proceeds	1,500,000
Principal Amount	250,000
Interest Rate per annum	1.00%
Fair value of warrants	282,767
Original Issue Discount	223,319
Carrying value	27,304
Price per share	$0.15
Note Payable	250,623
Note f
Debt Conversion [Line Items]
Issue Date	24-May-12
Proceeds from Covertible debenture	37,500
Principal Amount	15,900
Interest Rate per annum	8.00%
Note paid off	21,600
Note Payable	37,148	37,822
Note g
Debt Conversion [Line Items]
Issue Date	2-Sep-12
Principal Amount	12,500
Interest Rate per annum	8.00%
Note Payable	$26,676	$27,702

Convertible_Promissory_Notes_D2

Convertible Promissory Notes (Details Narrative) (Parenthetical)	12 Months Ended
	Dec. 31, 2014
Note a
Debt Conversion [Line Items]
Terms	Each purchase under this Agreement was to be made at 150% of the “Volume Weighted Average Price” (VWAP) on the day prior to the day the investment is made (the “Purchase Price”). Beginning on the date that is one hundred eighty (180) days following the Issue Date, Holder shall have the right to purchase Common Stock under this Agreement. Provided the VWAP is above $0.06,
Note d
Debt Conversion [Line Items]
Terms	The Company could settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principal amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principal amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note and accrued interest are convertible into common stock at a variable conversion price equal to 51% of the average of the three lowest closing bid prices for CelLynx Group, Inc’s common stock for a period of 10 days prior to the date of notice of conversion.
Note e
Debt Conversion [Line Items]
Terms	The Company may settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principal amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principal amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note and accrued interest are convertible into common stock at a variable conversion price equal to 51% of the average of the three lowest closing bid prices for CelLynx Group, Inc’s common stock for a period of 10 days prior to the date of notice of conversion.

Capital_Lease_Obligation_Detai

Capital Lease Obligation (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Capital Lease Obligations [Abstract]
Year 2015	$75,000
Year 2016	50,000
Total Minimum lease payments	125,000
Interest on Lease	-4,094
Capitalized valuation of R&D equipment	120,906
Amortization expense of R&D equipment	$58,802	$7,056

Operating_Lease_Obligation_Det

Operating Lease Obligation (Details Narrative) (USD $) (USD $)	Dec. 31, 2014
Capital Lease Obligations [Abstract]
Year 2015	$219,772
Year 2016	264,314
Year 2017	290,788
Year 2018	300,966
Year 2019	311,499
Aggregate over 5 years	53,380
Total Minimum lease payments	$1,440,719

Warrant_Activity_5BARz_Interna

Warrant Activity - 5BARz International Inc. (Details) (USD $) (5BARz, USD $)	12 Months Ended
	Dec. 31, 2014
5BARz
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding Warrants, beginning	47,580,103
Granted, Number of shares	34,920,294
Exercised, Number of shares
Cancelled, Number of shares	-540,000
Outstanding and exercisable, Number of Warrants	81,960,397
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding and exercisable, Weighted average exercise price	$0.26
Granted, Weighted average exercise price	$0.28
Exercised, Weighted average exercise price
Cancelled, Weighted average exercise price	$0.20
Outstanding and exercisable, Weighted average exercise price	$0.28
Beginning, Weighted Average Remaining Contractual Life, outstanding	1 year 6 months 4 days
Outstanding, Average Remaining Contractual Life	0 years 9 months 8 days

Warrant_Activity_5BARz_Interna1

Warrant Activity - 5BARz International Inc. (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014
Warrant Issued
Class of Warrant or Right [Line Items]
Warrants, granted	$30,728,629
Services
Class of Warrant or Right [Line Items]
Warrants, granted	2,525,000
Convertible Note Issuances
Class of Warrant or Right [Line Items]
Warrants, granted	$1,666,667

Options_Exercisable_5BARz_Deta

Options Exercisable 5BARz (Details) (5BARz, USD $)	12 Months Ended
	Dec. 31, 2014
5BARz
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning, Number of Options	4,000,000
Options, Granted	8,250,000
Options, Exercised
Options, Cancelled
Ending, Number of Options	12,250,000
Ending,Number of Options, outstanding and exercisable	10,150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price	$0.10
Weighted Average Exercise Price, Granted	$0.17
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Cancelled	$0
Weighted Average Exercise Price	$0.15
Beginning, Weighted Average Remaining Contractual Life, outstanding	8 years 3 months 8 days
Weighted Average Remaining Contractual Life, outstanding - granted	5 years 3 months 7 days
Ending, Weighted Average Remaining Contractual Life, outstanding - granted	6 years 4 months 2 days
Weighted Average Remaining Contractual Life, exercisable	6 years 4 months 2 days

Options_and_Warrants_5BARz_Det

Options and Warrants 5BARz (Details) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Aug. 01, 2014	Jul. 14, 2014	14-May-14	Jan. 13, 2014	17-May-13
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Fair value of stock options	$1,628,503	$221,643
5BARz
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Price			$0.17	$0.17	$0.16	$0.17	$0.10
Expected volatility			164.00%	167.00%	191.00%	225.00%	245.00%
Risk-free Interest			0.04%	0.04%	0.04%	0.04%	0.04%
Annual Dividend Yield			0.00%	0.00%	0.00%	0.00%	0.00%
Exepected Life (years)			10 years	5 years	5 years	5 years	10 years
Stock commitment, shares			2,000,000	100,000	2,000,000	4,150,000	4,000,000
Fair value of stock options			395,956	19,738	308,746	681,584	387,872
Stock options commitment, amount					$160,000
Share price			$0.17	$0.17	$0.17	$0.17	$0.10

Options_Exercisable_CelLynx_De

Options Exercisable CelLynx (Details) (Cellynx Group Inc., USD $)	12 Months Ended
	Dec. 31, 2014
Cellynx Group Inc.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning, Number of Options	65,000,000
Options, Granted	4,000,000
Ending,Number of Options, outstanding and exercisable	69,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price	$0.00
Weighted Average Exercise Price, Granted	$0.00
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price	$0.00
Weighted Average Remaining Contractual Life	4 years 3 months 0 days
Weighted Average Remaining Contractual Life, granted	4 years 6 months 3 days
Weighted Average Remaining Contractual Life	3 years 2 months 7 days

Warrant_Activity_CelLynx_Group

Warrant Activity - CelLynx Group, Inc. (Details) (USD $) (Cellynx Group, Inc., USD $)	12 Months Ended
	Dec. 31, 2014
Cellynx Group, Inc.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding Warrants, beginning	4,500,000
Granted, Number of shares
Exercised, Number of shares
Expired, Number of shares
Outstanding and exercisable, Number of Warrants	4,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding and exercisable, Weighted average exercise price	$0.96
Granted, Weighted average exercise price
Exercised, Weighted average exercise price
Expired, Weighted average exercise price
Outstanding and exercisable, Weighted average exercise price	$0.96
Outstanding, Average Remaining Contractual Life	0 years 1 month 2 days

Related_Party_transactions_Det

Related Party transactions (Details) (USD $)	0 Months Ended
	Aug. 18, 2014	Jul. 10, 2014	Jul. 08, 2014	Dec. 31, 2014	Dec. 31, 2013
Related Party Transactions [Abstract]
Proceeds from Note Payable		$40,000
Issuance of Common Stock	4,000,000	100,000,000	700,000
Issuance of common stock, value	385
Strike price	0.0003		0.2
Price per share		$0.00
Volatility	200.00%
Interest Rate	0.04%
Payment due to Related Party			$105,000

Investment_in_5BARz_AG_Details

Investment in 5BARz AG (Details Narrative) (5BARz AG, USD $)	0 Months Ended	12 Months Ended
	Oct. 06, 2011	Dec. 31, 2014	Dec. 31, 2013
5BARz AG
Subsidiary or Equity Method Investee [Line Items]
5BARz AG Common stock issued, shares	10,000,000
5BARz AG Common stock issued held by company, shares	5,100,000	9,417,000
5BARz AG Common stock issued held by officers and a consultant, shares	450,000
5BARz AG Common stock in escrow, shares	4,450,000
5BARz AG Common stock, Par Value	0.01 CHF	0.01 CHF
Common Stock Sold, in shares		11,000
Proceeds of Common Stock	$108,752	$36,069	$100,710
Acquired interest		94.20%	94.20%
Loss on assets written down		$14,583

Acquisition_of_CelLynx_Group_I

Acquisition of CelLynx Group, Inc.Description (Details Narrative) (USD $)	12 Months Ended		0 Months Ended	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jan. 07, 2011	Mar. 29, 2012
Subsidiary or Equity Method Investee [Line Items]
Amount of credit facility converted to capital stock of CelLynx Group, Inc.		($17,500)
Cellynx Group, Inc.
Subsidiary or Equity Method Investee [Line Items]
Common Stock recieved from CelLynx Group, Inc.			63,412,638
Purchase Price for common stok of CelLynx Group, Inc.			634,126
Cash consideration paid			170,000
Common Share of the registrant issued			1,250,000
Amount of credit facility converted to capital stock of CelLynx Group, Inc.				73,500
Amount of Shares of CelLynx Group, Inc. resulting from conversion of credit facility				350,000,000
Intrinsic value of embedded conversion feature				$381,500

Investment_of_CelLynx_Group_In

Investment of CelLynx Group, Inc.(Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014
13-Apr-12
Subsidiary or Equity Method Investee [Line Items]
Amount converted	$7,700
Shares issued	51,333,333
15-May-12
Subsidiary or Equity Method Investee [Line Items]
Amount converted	58,500
Shares issued	390,000,000
21-May-13
Subsidiary or Equity Method Investee [Line Items]
Amount converted	9,375
Shares issued	375,000,000
31-Mar-14
Subsidiary or Equity Method Investee [Line Items]
Amount converted	26,250
Shares issued	105,000,000
10-Jul-14
Subsidiary or Equity Method Investee [Line Items]
Amount converted	$31,620
Shares issued	155,000,000

Asset_Acquisition_Agreement_De

Asset Acquisition Agreement (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014
Revolving Line of Credit and Security Agreement
Amount of credit facility		$2,200,000
Amount of credit facility advanced	2,394,643
5BARz AG
Subsidiary or Equity Method Investee [Line Items]
Issuance of common stock, shares		9,000,000
Issuance of common stock, value		1,800,000
Price per share		$0.20
Revolving Line of Credit and Security Agreement
Amount of credit facility advanced		$2,865,032
Common Stock Recieved, share		1,489,745,971

Litigation_Details_Narrative

Litigation (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014
Labor Commission
Other Commitments [Line Items]
Date	7/19/10
Allegations	Back wages
Alleged Damages	$263,000
Accredited Members
Other Commitments [Line Items]
Date	9/11/14
Allegations	Unpaid fees
Alleged Damages	9,000
Legal Fees	$4,500
Common stock issued for debt, shares	255,000

Schedule_of_Accounts_payable_a

Schedule of Accounts payable and accrued expenses (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Servicing Liabilities at Fair Value [Line Items]
Accounts payable and accrued liabilities	$2,866,276	$1,450,167
Product development costs [Member]
Servicing Liabilities at Fair Value [Line Items]
Accounts payable and accrued liabilities	556,470
Consulting and wages [Member]
Servicing Liabilities at Fair Value [Line Items]
Accounts payable and accrued liabilities	912,045	261,361
Legal and administrative [Member]
Servicing Liabilities at Fair Value [Line Items]
Accounts payable and accrued liabilities	165,587	56,471
Acquired liabilities B Cellynx 2012 [Member]
Servicing Liabilities at Fair Value [Line Items]
Accounts payable and accrued liabilities	1,072,328	1,077,703
Other [Member]
Servicing Liabilities at Fair Value [Line Items]
Accounts payable and accrued liabilities	$159,846	$54,632

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (Subsequent Event, USD $)	0 Months Ended						3 Months Ended
	Mar. 03, 2015		Feb. 20, 2015	Feb. 02, 2015	Jan. 12, 2015	Jan. 13, 2015	Mar. 20, 2015	Mar. 06, 2015
Subsequent Event
Subsequent Event [Line Items]
Units Issued							5,622,500
Proceeds from Sale of Warrants							$281,125
Convertible note arrangement	350,000	[1]
Price of Stock			$0.05	$0.10		$0.07	$0.05
Shares issued for Services, shares			180,000	75,000
Shares issued for services, value			9,000	7,500
Aggregate funding	175,000							400,000
Discount percentage	0.1
Original Issue Discount	17,500
Common stock issued for debt, shares						331,986
Settlement of debt for common stock				180,000		23,000
Note balance payoff						73,587
Account payable settlement				$9,000
Stock options, authorized								400,000
Interest Rate per annum	10.00%
Price per warrant							$0.30
Strock option, shares								12,441,667
Purchase of new entity					5BARz India
Percentage Owned					99.00%
[1]	The loan may be repaid at any time during the first six months of the note term, at a prepayment premium on day 90 of 115%, increasing by 5% each month to month 6. After month three, if the note is not repaid, a one time interest charge of 10% will be assessed. After 6 months, the note is convertible into common stock of the issuer at a discount to market of 35%, with the market defined as the lowest trade price for a period of 25 days prior to the conversion, with a conversion floor price at no lower than $0.001.